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A B S T R A C T
Background
Antibiotics provide only modest benefit in treating sore throat, although effectiveness increases in participants with positive throat
swabs for group A beta-haemolytic streptococci (GABHS). It is unclear which antibiotic is the best choice if antibiotics are indicated.
Objectives
To assess the evidence on the comparative efficacy of different antibiotics in: (a) alleviating symptoms (pain, fever); (b) shortening
the duration of the illness; (c) preventing relapse; and (d) preventing complications (suppurative complications, acute rheumatic fever,
post-streptococcal glomerulonephritis). To assess the evidence on the comparative incidence of adverse effects and the risk-benefit of
antibiotic treatment for streptococcal pharyngitis.
Search methods
We searched CENTRAL (2016, Issue 3), MEDLINE Ovid (1946 to March week 3, 2016), Embase Elsevier (1974 to March 2016),
and Web of Science Thomson Reuters (2010 to March 2016). We also searched clinical trials registers.
Selection criteria
Randomised, double-blind trials comparing different antibiotics and reporting at least one of the following: clinical cure, clinical relapse,
or complications or adverse events, or both.
Data collection and analysis
Two review authors independently screened trials for inclusion, and extracted data using standard methodological procedures as
recommended by Cochrane. We assessed risk of bias of included studies according to the methods outlined in the Cochrane Handbook
for Systematic Reviews of Interventions and used the GRADE tool to assess the overall quality of evidence for the outcomes.
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Main results
We included 19 trials (5839 randomised participants); seven compared penicillin with cephalosporins, six compared penicillin with
macrolides, three compared penicillin with carbacephem, one trial compared penicillin with sulphonamides, one trial compared
clindamycin with ampicillin, and one trial compared azithromycin with amoxicillin in children. All included trials reported clinical
outcomes. Reporting of randomisation, allocation concealment, and blinding was poor in all trials. The overall quality of the evidence
assessed using the GRADE tool was low for the outcome ’resolution of symptoms’ in the intention-to-treat (ITT) analysis and very
low for the outcomes ’resolution of symptoms’ of evaluable participants and for adverse events. We downgraded the quality of evidence
mainly due to lack of (or poor reporting of ) randomisation or blinding, or both, heterogeneity, and wide confidence intervals (CIs).
There was a difference in symptom resolution in favour of cephalosporins compared with penicillin (evaluable patients analysis odds
ratio (OR) for absence of resolution of symptoms 0.51, 95% CI 0.27 to 0.97; number needed to treat to benefit (NNTB) 20, N = 5, n
= 1660; very low quality evidence). However, this was not statistically significant in the ITT analysis (OR 0.79, 95% CI 0.55 to 1.12;
N = 5, n = 2018; low quality evidence). Clinical relapse was lower for cephalosporins compared with penicillin (OR 0.55, 95% CI 0.30
to 0.99; NNTB 50, N = 4, n = 1386; low quality evidence), but this was found only in adults (OR 0.42, 95% CI 0.20 to 0.88; NNTB
33, N = 2, n = 770). There were no differences between macrolides and penicillin for any of the outcomes. One unpublished trial in
children found a better cure rate for azithromycin in a single dose compared to amoxicillin for 10 days (OR 0.29, 95% CI 0.11 to 0.73;
NNTB 18, N = 1, n = 482), but there was no difference between the groups in ITT analysis (OR 0.76, 95% CI 0.55 to 1.05; N = 1,
n = 673) or at long-term follow-up (evaluable patients analysis OR 0.88, 95% CI 0.43 to 1.82; N = 1, n = 422). Children experienced
more adverse events with azithromycin compared to amoxicillin (OR 2.67, 95% CI 1.78 to 3.99; N = 1, n = 673). Compared with
penicillin carbacephem showed better symptom resolution post-treatment in adults and children combined (ITT analysis OR 0.70,
95% CI 0.49 to 0.99; NNTB 14, N = 3, n = 795), and in the subgroup analysis of children (OR 0.57, 95% CI 0.33 to 0.99; NNTB
8, N = 1, n = 233), but not in the subgroup analysis of adults (OR 0.75, 95% CI 0.46 to 1.22, N = 2, n = 562). Children experienced
more adverse events with macrolides compared with penicillin (OR 2.33, 95% CI 1.06 to 5.15; N = 1, n = 489). Studies did not report
on long-term complications so it was unclear if any class of antibiotics was better in preventing serious but rare complications.
Authors’ conclusions
There were no clinically relevant differences in symptom resolution when comparing cephalosporins and macrolides with penicillin
in the treatment of GABHS tonsillopharyngitis. Limited evidence in adults suggests cephalosporins are more effective than penicillin
for relapse, but the NNTB is high. Limited evidence in children suggests carbacephem is more effective than penicillin for symptom
resolution. Data on complications are too scarce to draw conclusions. Based on these results and considering the low cost and absence
of resistance, penicillin can still be regarded as a first choice treatment for both adults and children. All studies were in high-income
countries with low risk of streptococcal complications, so there is need for trials in low-income countries and Aboriginal communities
where risk of complications remains high.
P L A I N L A N G U A G E S U M M A R Y
Different antibiotics for group A streptococcal pharyngitis
Review question
Wewanted to know which antibiotic was more effective in treating sore throats caused by bacteria (group A beta-haemolytic streptococci
(GABHS)).
Background
Most sore throats are caused by viruses, but many people carry throat bacteria, sometimes causing bacterial throat infection.
GABHS infection can have serious complications including rheumatic fever and kidney disease. Antibiotics are often prescribed to
prevent complications, but provide modest benefit for sore throat, even if GABHS are present. Most throat infections are self-limiting
and complication risks is extremely low formost people in high-income countries.However, sometimes antibiotics are needed. Penicillin,
a cheap antibiotic, has been used to treat GABHS for many years. GABHS resistance to penicillin is rare.
Search date
We searched the literature to March 2016.
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Study characteristics
We included 19 trials (18 publications) that involved 5835 people. Trials studied different antibiotics for people with sore throat who
tested positive for GABHS, and were aged from one month to 80 years. Nine trials included only children; and nine included people
aged 12 years or older. Most studies were published over 15 years ago; all but one reported on clinical outcomes.
Study funding sources
Thirteen trials were supported by drug study funding - some received grants - others included people employed by drug companies.
Five studies did not report funding.
Key results
Antibiotic effects were similar, and all caused side effects (such as nausea and vomiting, rash), but there was no strong evidence to
show meaningful differences between antibiotics. Studies did not report on long-term complications so it was unclear if any class of
antibiotics was better in preventing serious but rare complications.
All studies were in high-income countries with low risk of streptococcal complications, so there is a need for trials in low-income
countries and Aboriginal communities where risk remains high. Our review supports the use of penicillin as a first choice antibiotic in
patients with throat infections caused by GABHS.
Quality of the evidence
Evidence quality was low or very low for all outcomes when macrolides or cephalosporins were compared with penicillin. Evidence
quality was downgraded because of concerns about randomisation and blinding, wide confidence intervals (estimates were not very
precise) and statistical differences among studies that may impact on the validity of the estimate. Most study authors did not report
enough information about methods to be sure there was no bias.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cephalosporins compared to penicillin for group A streptococcal pharyngitis
Patient or population: group A streptococcal pharyngit is
Setting: outpat ients
Intervention: cephalosporin
Comparison: penicillin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with penicillin Risk with
Cephalosporin
Resolut ion of symp-
toms post-treatment
(ITT analysis)
Study populat ion OR 0.79
(0.55 to 1.12)
2018
(5 RCTs)
⊕⊕©©
LOW 12
245 per 1,000 204 per 1,000
(151 to 267)
Resolut ion of symp-
toms post-treatment
(ITT analysis) - Adults
Study populat ion OR 0.78
(0.60 to 1.01)
1163
(2 RCTs)
⊕⊕©©
LOW 12
320 per 1,000 268 per 1,000
(220 to 322)
Resolut ion of symp-
toms post-treatment
(ITT analysis) - Children
Study populat ion OR 0.83
(0.40 to 1.73)
855
(3 RCTs)
⊕©©©
VERY LOW 123
167 per 1,000 143 per 1,000
(74 to 258)
Res-
olut ion of symptoms
post-treatment (evalu-
able part icipants)
Study populat ion OR 0.51
(0.27 to 0.97)
1660
(5 RCTs)
⊕©©©
VERY LOW 123
112 per 1,000 60 per 1,000
(33 to 109)
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Incidence of
relapse (evaluable par-
t icipants)
Study populat ion OR 0.55
(0.30 to 0.99)
1386
(4 RCTs)
⊕⊕©©
LOW 12
46 per 1,000 26 per 1,000
(14 to 45)
Adverse events (ITT
analysis)
Study populat ion OR 0.94
(0.27 to 3.25)
1279
(3 RCTs)
⊕©©©
VERY LOW 123
193 per 1,000 184 per 1,000
(61 to 438)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 unclear randomisat ion and blinding
2 wide conf idence intervals
3 heterogeneity
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B A C K G R O U N D
Description of the condition
Pharyngitis is a common upper respiratory tract infection. Antibi-
otics are often prescribed to treat this condition. Patients usually
consult a physician with the complaint of sore throat. A previous
Cochrane review comparing the effect of antibiotics to placebo in
participants with or without GABHS sore throat pointed to the
self-limiting nature of an acute sore throat (even in cases of positive
GABHS culture) (Spinks 2013). Antibiotics provide only mod-
est benefit when prescribed for sore throat. The effect of antibi-
otic treatment was increased in participants with positive throat
swabs for GABHS. The streptococci-positive participants are only
a small proportion of all participants with sore throat. Neverthe-
less, in many countries antibiotics are prescribed for most people
who have a sore throat (Cars 2001; Linder 2001). Given the high
consumption of antibiotics for this condition, a rational approach
would be to reserve treatmentwith antibiotics for participants with
proven presence, or a high likelihood of GABHS (Cooper 2001;
Snow 2001). However, clinical scoring systems are somewhat lim-
ited in their ability to correctly target GABHS-positive patients
(McIsaac 1998), and the usefulness of rapid assay tests depends on
the prevalence of GABHS in the population (Sonnad 1999); jus-
tification of its cost-effectiveness is unclear (Gerber 2004; Neuner
2003).
Description of the intervention
The slight benefit of treatment with antibiotics in patients with
GABHS sore throat may be considered relevant. When antibi-
otics are indicated, a choice needs to be made. In that case, sev-
eral aspects need to be considered, such as the comparative ben-
efit-harm balance, costs, and local antimicrobial resistance pat-
terns. Many guidelines recommend penicillin as a first choice,
with erythromycin preferred for people who are allergic to peni-
cillin (Cooper 2001; Snow 2001). To date, resistance of GABHS
to penicillin has only been documented incidentally (Devi 2011;
Gerber 2009b; Ibrahim 2014), and resistance to erythromycin
is still low (Cooper 2001). Considering the growing problem of
antibiotic resistance for other pathogens, this responsiveness of
GABHS should not be endangered (Wise 1998). Penicillin and
erythromycin are cheap and the most cost-effective option. De-
spite this, physicians continue to prescribe broad-spectrum antibi-
otics, including recently marketed ones. It is not clear if these an-
tibiotics have any substantial clinical benefit over penicillin (and
erythromycin).
Why it is important to do this review
Internationally, guidelines recommend using penicillin as first
choice when choosing to treat people with acute sore throat (sus-
pected to be caused by GABHS) with antibiotics (Matthys 2007).
However, some argue that cephalosporins are more effective and
should therefore be preferred (Casey 2004). Many physicians ar-
gue that occurrence of penicillin allergy should be taken into ac-
count when making a choice for an antibiotic. This review looked
for evidence of penicillin allergy occurring in the available trials.
In addition, in the presence of documented penicillin allergy, the
side effect profile of eligible antibiotics can guide choice. There-
fore, to provide healthcare providers with sufficient information
to make an evidence-based choice, both treatment benefits and
adverse events are compared.
O B J E C T I V E S
To assess the evidence on the comparative efficacy of different an-
tibiotics in: (a) alleviating symptoms (pain, fever); (b) shortening
the duration of the illness; (c) preventing relapse; and (d) prevent-
ing complications (suppurative complications, acute rheumatic
fever, post-streptococcal glomerulonephritis). To assess the evi-
dence on the comparative incidence of adverse effects and the risk-
benefit of antibiotic treatment for streptococcal pharyngitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised, double-blind, controlled trials comparing at least
two different classes of antibiotics.
Types of participants
Adults and children of all ages presenting with symptoms of sore
throat and with an infection caused by GABHS confirmed by a
throat culture, rapid test or both.
Types of interventions
Antibiotics of one class compared with another class.
Types of outcome measures
The focus was on outcome measures relevant for patients.
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Primary outcomes
1. Resolution of symptoms (cure or improvement of signs and
symptoms, which could include sore throat, fever, feeling ill,
etc.) post-treatment
Secondary outcomes
1. Sore throat
2. Fever
3. Duration of illness
4. Incidence of relapse
5. Incidence of complications (suppurative complications,
acute rheumatic fever, post-streptococcal glomerulonephritis)
6. Adverse events
Search methods for identification of studies
Electronic searches
For this update we searched theCochrane Acute Respiratory Infec-
tions Group’s Specialised Register (25March 2016); the Cochrane
Central Register of Controlled Trials (CENTRAL; 2016, Issue
11), in the Cochrane Library (searched 25 March 2016); MED-
LINEOvid (1966 toMarch week 3 2016); Embase Elsevier (1974
to 25 March 2016) and Web of Science Thomson Reuters (2010
to 25 March 2016). Search strategies for previous versions of this
review are presented in Appendix 1. Details of the current MED-
LINE and CENTRAL search strategy are in Appendix 2, Embase
is in Appendix 3, and Web of Science is in Appendix 4.
We did not impose any language or publication restrictions.
Searching other resources
We searched the World Health Organization International Clini-
cal Trials Registry Platform (WHO ICTRP), and theUSNational
Institutes of Health Ongoing Trials Register for completed and
ongoing trials (www.clinicaltrials.gov). We used the terms strep-
tococcal AND pharyngitis (latest search 25March 2016). We also
searched reference sections of the identified reviews and trials for
additional trials; independent sources of drug information (jour-
nals of the International Society of Drug Bulletins (electronically
and by hand); and proceedings of meetings and conferences for
additional references of trials. We contacted pharmaceutical com-
panies producing antibiotics applied in treating pharyngitis for
published or unpublished trials on their products, and experts in
the field for additional references.
Data collection and analysis
Selection of studies
Two review authors (MVD, NK) independently assessed all trials
with relevant titles or abstracts, or both, identified by the search to
determine which met the inclusion criteria. We excluded all trials
that did not meet our inclusion criteria. Trials that were closely
assessed for inclusion but subsequently excluded are listed in the
Characteristics of excluded studies table. The search results are
reported in a PRISMA flow diagram (Figure 1).
7Different antibiotic treatments for group A streptococcal pharyngitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Data extraction and management
Two review authors (MVD, NK) independently extracted data,
using a standard checklist we developed for the review. The stan-
dard data extraction form included the following general infor-
mation: published/unpublished, title, authors, source, contact ad-
dress, country, language of publication, year of publication, du-
plicate publications, sponsoring, and setting. It also included data
on the following domains:
1. Methods: randomisation procedure, allocation, blinding
(participants, people administering treatment, outcome
assessors), duration of study, design, analysis (intention-to-treat
(ITT)).
2. Participants: number, age, diagnostic criteria, history,
baseline characteristics.
3. Interventions: dose, route, timing, duration; comparison
group.
4. Outcomes: outcomes specified above, any other outcomes
assessed, other events, length of follow-up.
5. Results: for outcomes and times of assessment (including a
measure of variation).
Assessment of risk of bias in included studies
Two review authors (MVD, NK) assessed the methodological
quality of the included trials by using Cochrane’s risk of bias tool
(Higgins 2011). The same review authors independently assessed
each trial.We assessed risk of bias for: selection bias (random num-
ber generation and allocation concealment), performance and de-
tection bias (blinding), attrition bias (incomplete outcome data),
and reporting bias (selective reporting). We assessed studies as low
risk of bias (methods clearly described and deemed adequate), high
risk of bias (methods described and inadequate or not described
and deemed likely to be inadequate), or unclear bias (insufficient
information to assess the methods, however no obvious indication
for use of inadequate methods).
Measures of treatment effect
We used Review Manager 5 software for statistical analysis and
data pooling (RevMan 2014). If possible, we summarised data in
a meta-analysis and performed analyses according to ITT analy-
sis. This means that the number of participants randomised was
used as the denominator for each outcome. We considered the
participants for whom an outcome was not reported as treatment
failures. For dichotomous outcomes, we expressed results as ORs,
with 95% CIs. For statistically significant results we calculated
NNTB and NNTH where possible.
Unit of analysis issues
We did not include any cluster-randomised studies. All included
studies reported outcomes at the level of the randomised unit, the
individual patient.
Dealing with missing data
We assessed the impact of missing data on the overall outcome
of the meta-analysis by comparing analysis of on-treatment (or
evaluable patients) and ITT data.
Assessment of heterogeneity
We assessed heterogeneity among trial results by calculating a Chi²
test (significance defined as P < 0.10) and the I² statistic (Higgins
2003).
Assessment of reporting biases
We did not identify a sufficient number of studies to assess the
presence of publication bias by means of a funnel plot.
Data synthesis
We pooled dichotomous data using a random-effects model
(Higgins 2011). We used a random-effects model for pooling
(DerSimonian 1986), but in the absence of statistical heterogene-
ity (using a cut-off point of I² < 20%), we also pooled data using
the fixed-effect model and compared outcomes (Mantel 1959).
We used RevMan 2014 software for pooling.
GRADE and ’Summary of findings’ table
For assessment of the overall quality of evidence for the pooled
studies, we used the GRADE approach (Atkins 2004), with
GRADEpro software (GRADEproGDT 2014). We used the five
GRADE considerations (study limitations, consistency of ef-
fect, imprecision, indirectness, and publication bias) to assess the
quality of evidence as it relates to the studies which contribute
data to the meta-analyses for the prespecified outcomes. We cre-
ated summary of findings tables for the following comparisons:
cephalosporin versus penicillin (Summary of findings for themain
comparison; Analysis 1.1; Analysis 1.2; Analysis 1.6; Analysis 1.8)
and macrolide versus penicillin (Summary of findings 2; Analysis
2.1; Analysis 2.2; Analysis 2.5; Analysis 2.6).We assessed the qual-
ity of evidence for the primary outcome (resolution of symptoms,
both ITT and evaluable patient analysis), and secondary outcomes
(incidence of relapse and incidence of adverse events). We justi-
fied all decisions to down- or up-grade the quality of studies using
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footnotes to aid readers’ understanding of the review where nec-
essary.
Subgroup analysis and investigation of heterogeneity
We stratified the trials into subcategories according to the compar-
isons between different classes of antibiotics. For each comparison
we reported and pooled the predefined outcomes, if possible, in
a meta-analysis. We performed subgroup analyses for trials with
children versus adults.
We reported ITT data for clinical outcomes and analysis of evalu-
able participants (i.e. only including in the analysis participants for
whom outcome reporting was complete) to illustrate any differ-
ences between analysis methods. Analysis of relapse incidence was
analysed by including only evaluable participants; an ITT analysis
would have seriously overestimated the importance of relapse, and
results would not be relevant to clinical practice.
Sensitivity analysis
We performed a sensitivity analysis of the impact of heterogeneity
on the overall effect estimate by first pooling all studies and sub-
sequently removing studies one by one, starting with the studies
that appeared (by inspection of the forest plot) to be contributing
to the heterogeneity. We also performed sensitivity analysis by ap-
plying both random-effects and fixed-effect models in the absence
of statistical heterogeneity (I² < 20%). A meaningful sensitivity
analysis was only possible for resolution of symptoms in the com-
parison of cephalosporin versus penicillin.
R E S U L T S
Description of studies
Results of the search
We retrieved 385 search results from our electronic searches toOc-
tober 2012. We retrieved an additional 216 records in the Decem-
ber 2014 search and anther 258 records in theMarch 2016 search.
We identified one additional trial through aGoogle search (Muller
1992). We identified two references to completed (unpublished)
studies on ClinicalTrials.gov in the 2014 search (NCT00643149;
NCT00393744). We reviewed a total of 77 trials for this review.
Of these, 21 met the predefined inclusion criteria. Two of the 21
papers reported different outcomes of the same study and were
considered as one single study (Norrby 2002). The unpublished
report of one study registered and marked as completed on Clin-
icalTrials.gov was made available by Pfizer upon request in 2013
and was included in the 2016 update (NCT00643149). Of the
two additional studies that we identified in theMarch 2016 search,
we excluded one (Stillerman 1970), and one was available in ab-
stract form only and is awaiting classification pending informa-
tion from the authors (Eslami 2014). See PRISMA flow diagram
(Moher 2009; Figure 1).
Included studies
We included 18 trials in the first version of this review (van Driel
2010). Henness 1982 reported two separate trials and we split this
into two parts to clarify which trial was assessed (Henness 1982-
study 1; Henness 1982-study 2). We identified one new study
in the 2012 update (NCT00643149), and no new studies in the
2014 update. We did not add any new studies in the 2016 update.
We included a total of 19 trials in this review. Most included trials
were conducted in the 1990s, three in the 1980s (Henness 1982-
study 1; Henness 1982-study 2; Randolph 1985), and two in the
1970s (Jackson 1973; Trickett 1973). Only two trials were more
recent (Norrby 2002; NCT00643149). All but one trial reported
clinical outcomes (Henness 1982-study 2).
Contacting pharmaceutical companies did not result in any addi-
tional published or unpublished data (only one company replied);
neither did contacting authors or experts in the field. We identi-
fied the NCT00643149 study through searching a clinical trials
register and we subsequently obtained a report from the manufac-
turer.
All but two of the included studies compared penicillin with an-
other antibiotic class. Henness 1982 compared penicillin V with
cefadroxil in both study 1 and study 2, but added two additional
study arms in study 2 (erythromycin, benzathine penicillinG/pro-
caine penicillin). Jackson 1973 compared clindamycin with ampi-
cillin and NCT00643149 compared azithromycin with amoxi-
cillin.
The included trials investigated a total of 5839 randomised partic-
ipants with acute GABHS tonsillopharyngitis. Participants’ ages
ranged from one month to 80 years. Nine trials included only, or
predominantly, children (Disney 1992a; Disney 1992b; Henness
1982-study 1; Henness 1982-study 2; Jackson 1973; O’Doherty
1996; NCT00643149; Randolph 1985; Reed 1991). Ten trials
included participants who were at least 12 years of age or older
(Bachand 1991; Carbon 1995; Levenstein 1991;McCarty 1992a;
Muller 1992; Nemeth 1999; Norrby 2002; Stein 1991; Trickett
1973; Watkins 1997). In Reed 1991, approximately 80% of par-
ticipants were under 15 years of age and therefore included in the
subgroup analysis for children. In Muller 1992, 90% of partici-
pants were aged over 12 years; however, because results were not
stratified by age group, this study was included in the adult sub-
group analysis.
All trials included only participants with confirmed acute GABHS
tonsillopharyngitis. Confirmation of the presence of GABHS in
participants with clinical signs of tonsillopharyngitis was mostly
performed first by a rapid immunoassay test and reconfirmed with
a throat culture. In five trials, the confirmation of GABHS ton-
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sillopharyngitis was carried out only by a throat culture (Henness
1982-study 1; Henness 1982-study 2; Jackson 1973; Randolph
1985; Trickett 1973), and in two trials only with a rapid im-
munoassay test (O’Doherty 1996; Stein 1991). All but one trial
reported on clinical outcomes. Trickett 1973 only reported bac-
teriological outcomes, but was included in the meta-analysis on
adverse effects.
Clinical outcomes, in most studies defined as complete resolution
of signs and symptoms (Characteristics of included studies), were
assessed at various time points, but mostly measured between five
to 10 days following the end of antibiotic treatment. Therefore,
post-treatment the outcome ’post-treatment clinical efficacy’ (i.e.
assessment of signs and symptoms after completion of the treat-
ment course) was pooled. Randolph 1985 reported clinical effect
within the first 24 hours of treatment. NCT00643149 assessed
clinical effects on days 24 to 28 after starting the study drug.
Three trials reported on specific symptoms, such as sore throat and
fever (Bachand 1991; Levenstein 1991; Randolph 1985). None
reported data on the duration of illness. Henness 1982-study 2
did not report any clinical outcomes.
Twelve trials reported the incidence of clinical relapse (Bachand
1991; Carbon 1995; Disney 1992a; Disney 1992b; Levenstein
1991;McCarty 1992a;Muller 1992;Nemeth1999;Norrby 2002;
O’Doherty 1996; Reed 1991; Stein 1991). The definition of clini-
cal relapse varied slightly; from “pretreatment signs and symptoms
resolved but reappeared” (Bachand 1991; Carbon 1995; Disney
1992b; Levenstein 1991; McCarty 1992a; Muller 1992; Nemeth
1999; Norrby 2002; Stein 1991) or “initial improvement or al-
leviation of symptoms, but subsequent worsening or recurrence”
(McCarty 1992a; Watkins 1997) to “new infection with differ-
ent serotype” (Disney 1992a). One study defined clinical cure as
“clinical improvement within first 24 hours of therapy and all
follow-up cultures no S pyogenes” (Henness 1982-study 1). Two
studies used the physician’s assessment of symptoms as outcome
(Randolph 1985; Reed 1991).
Four trials reported complications occurring during longer follow-
up (Carbon 1995; Jackson 1973; McCarty 1992a; Muller 1992).
Fifteen trials mentioned adverse effects reported during treatment.
Jackson 1973 only reported bacteriological outcomes and clinical
adverse events.
The use of antipyretic analgesics was allowed in four trials
(Bachand 1991; Disney 1992b;Muller 1992;Watkins 1997), pro-
hibited in two (Carbon 1995; Randolph 1985), and not stated in
the other 13 trials.
The percentage of patients who dropped out before outcome mea-
surement varied. Some studies did not seem to have any drop-
outs (Henness 1982-study 1; Henness 1982-study 2; Randolph
1985) or lost 20% or fewer of the randomised participants at
the time of outcome evaluation (Carbon 1995; Disney 1992b;
Jackson 1973; Levenstein 1991; Norrby 2002; NCT00643149;
Reed 1991). Six studies reported drop out rates between 20%
and 30% (Bachand 1991; McCarty 1992a; Muller 1992; Nemeth
1999; O’Doherty 1996; Stein 1991), and in Watkins 1997, re-
portedly 38% of patients dropped out before the end of the study.
The most commonly reported reason for dropout was negative
culture for GABHS.
Excluded studies
We excluded 57 studies. The most common reason for ex-
clusion (38 trials) was no or inadequate blinding (Adam
1994; Adam 1995; Adam 1996; Adam 2000a; Adam 2000b;
Adam 2001; Aujard 1995; Bottaro 2012; Cohen 2002; Denny
1953; Dykhuizen 1996; Esposito 2002; Feder 1999; Gerber
1986; Gooch 1993; Hamill 1993; Holm 1991; Howe 1997;
Kuroki 2013; Lennon 2008; McCarty 1992b; McCarty 1994;
Milatovic 1991; Milatovic 1993; Pacifico 1996; Perkins 1969;
Pichichero 2000; Pichichero 2008; Portier 1990; Portier 1994;
NCT00393744; Sakata 2008; Shapera 1973; Shvartzman 1993;
Stillerman 1986; Tack 1997; Tack 1998; Uysal 2000). Seven trials
did not compare at least two different classes of antibiotics (Breese
1974; Disney 1979; Matsen 1974; McIsaac 2004; Rimoin 2011;
Siegel 1961; Zwart 2000). In two trials the included participants
did not exclusively have acute GABHS tonsillopharyngitis (Davies
1995; Standaert 1997), and one trial included patients with recur-
rent tonsillitis (Roos 1997). Two trials did not report any clinical
outcomes (Gerber 1999a; Stillerman 1970); one was a meta-anal-
ysis (Cruz 2011); two were reviews (Stelter 2014; Van Brusselen
2014); and four were not RCTs (Del Mar 2008; DeMeyere 1992;
Granizio 2008; Haverkorn 1971).
Risk of bias in included studies
Risk of bias assessment is reported in Characteristics of included
studies and illustrated in Figure 2 and Figure 3.Only three trials re-
ported ITT analysis for efficacy outcomes (Disney 1992a; Norrby
2002; Randolph 1985). One trial reported carrying out an ITT
analysis, but post-randomisation exclusions were not included in
the efficacy analysis (Carbon 1995). All trial authors used an ITT
analysis for adverse effects.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All trials were randomised, but only four described methods of
randomisation or allocation concealment, or both (Jackson 1973;
Randolph 1985; Reed 1991; Watkins 1997).
Random sequence generation was described and deemed adequate
in two studies (Randolph 1985; Watkins 1997) and not described
(assessed as unclear risk) in the remaining studies.
Allocation concealment was described and assessed as adequate in
four studies (Jackson 1973; Randolph 1985; Reed 1991; Watkins
1997) and not described (assessed as unclear risk) in the other
studies.
Blinding
All trials were double-blinded and methods of blinding were de-
scribed in 14 trials (Disney 1992a; Disney 1992b; Jackson 1973;
Levenstein 1991; McCarty 1992a; Muller 1992; Norrby 2002;
O’Doherty 1996; NCT00643149; Randolph 1985; Reed 1991;
Stein 1991; Trickett 1973; Watkins 1997).
Blinding of participants and personnel was reported and assessed
as low risk of bias in 15 trials (Bachand 1991; Disney 1992a;
Disney 1992b; Jackson 1973; Levenstein 1991; McCarty 1992a;
Muller 1992; NCT00643149; Norrby 2002; O’Doherty 1996;
Randolph 1985; Reed 1991; Stein 1991; Trickett 1973; Watkins
1997). In four studies (Carbon 1995; Henness 1982-study 1;
Henness 1982-study 2; Nemeth 1999) this was not reported and
assessed as unclear risk of bias.
Blinding of outcome assessors was reported and assessed as low risk
of bias in only one trial (Randolph 1985). This was not reported
and hence assessed as unclear risk of bias in all other included
studies.
Incomplete outcome data
The post-randomisation dropout rate was high in most trials. In
12 trials the proportion of dropouts was more than 20% (Bachand
1991; Henness 1982-study 1; Jackson 1973; Levenstein 1991;
McCarty 1992a; Muller 1992; NCT00643149; Nemeth 1999;
O’Doherty 1996; Reed 1991; Stein 1991;Watkins 1997), ranging
from 21.5% in McCarty 1992a to 48.5% in Levenstein 1991. In
the outcome analysis most trials included only participants with
complete outcome data. This may have had an important impact
on the effect measured, and therefore, these studies were assessed
as high risk of attrition bias.
Only four trials reported an ITT analysis with all randomised par-
ticipants included in the analysis of the clinical outcome (Disney
1992a; Disney 1992b; Norrby 2002; Randolph 1985). These tri-
als had minimal to no dropouts (0 or 1 participant) and were as-
sessed as low risk of attrition bias. Carbon 1995, Henness 1982-
study 2 and Trickett 1973 were also assessed as low risk of attrition
bias because of a low post-randomisation dropout rate.
None of the studies were assessed as unclear risk of attrition bias.
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Selective reporting
All included studies were assessed as unclear risk for selective re-
porting; pre-publication protocols were not available.
Other potential sources of bias
Eleven trials reported sponsorship by a pharmaceutical company
(Disney 1992a; Disney 1992b; Jackson 1973; McCarty 1992a;
Muller 1992; Nemeth 1999; Norrby 2002; Randolph 1985; Reed
1991; Trickett 1973; Watkins 1997). NCT00643149 was un-
published and obtained from the company that conducted the
trial (Pfizer). Authors of six trials were reported to be employ-
ees of a pharmaceutical company (Bachand 1991; Disney 1992b;
Henness 1982-study 1; Henness 1982-study 2; Nemeth 1999;
Watkins 1997), and in three of those, the employing pharmaceuti-
cal company was not reported as a funding source (Bachand 1991;
Henness 1982-study 1; Henness 1982-study 2). These fourteen
trials were assessed as high risk of bias in this domain. The remain-
ing five trials did not mention funding sources and were assessed
as ’unclear risk of bias’ in this domain.
Six trialsmentioned that ethics approval was obtained for the study
(Bachand 1991; Levenstein 1991; Muller 1992; Nemeth 1999;
Norrby 2002; O’Doherty 1996), and seven trials reported that
informed consent was obtained from participants or guardians
(Levenstein 1991; McCarty 1992a; Muller 1992; Nemeth 1999;
Norrby 2002; O’Doherty 1996; Reed 1991).
Effects of interventions
See: Summary of findings for the main comparison
Cephalosporins compared to penicillin for group A streptococcal
pharyngitis; Summary of findings 2 Macrolides compared to
penicillin for group A streptococcal pharyngitis
1. Cephalosporin versus penicillin
Six trials contributed to the pooled analysis within this comparison
(Carbon 1995; Disney 1992a; Henness 1982-study 1; Nemeth
1999; Randolph 1985; Reed 1991). We assessed the overall qual-
ity of evidence for the primary outcome, resolution of symptoms
post-treatment as low for the ITT analysis in the total study popu-
lation and in the subgroup analysis for adults, but very low for the
analysis of evaluable patients and ITT analysis in children. The
quality of the pooled effect estimate was assessed as low for the
outcome incidence of relapse (evaluable patients) and very low for
the outcome adverse events (ITT analysis). We downgraded the
quality due to unclear randomisation and blinding, wide confi-
dence intervals, and heterogeneity when pooling the studies (see
Summary of findings for the main comparison).
1.1. Primary outcome: Resolution of symptoms post-
treatment
Six trials reported on the resolution of symptoms at various points
in time (Carbon 1995; Disney 1992a; Henness 1982-study 1;
Nemeth 1999; Randolph 1985; Reed 1991). See also Summary
of findings for the main comparison.
Five trials measured resolution of symptoms at the end of treat-
ment (2 to 15 days or more post-treatment); two trials in adults
(Carbon 1995; Nemeth 1999), and three in children (Disney
1992b; Henness 1982-study 1; Reed 1991). The ITT analysis in-
cluded 2018 participants and showed no difference between treat-
ments (OR 0.79, 95% CI 0.55 to 1.12; low quality evidence;
Analysis 1.1; Summary of findings for the main comparison). The
effect in adults (OR 0.78, 95% CI 0.60 to 1.01; N = 2, n = 1163;
low quality evidence) was similar to that in children (OR 0.83,
95% CI 0.40 to 1.73; N = 3, n = 855; low quality evidence).
The result of the analysis of evaluable participants only showed
an effect in favour of treatment with cephalosporins (OR 0.51,
95% CI 0.27 to 0.97; ARD 0.05, NNTB 20, n = 1660; very low
quality evidence; Analysis 1.2; Summary of findings for the main
comparison). However, the estimates of effect in adults (OR 0.56,
95% CI 0.24 to 1.32; N = 2, n = 880) and in children (OR 0.46,
95% CI 0.14 to 1.52; N = 3, n = 780) analysed separately revealed
no statistically significant differences between treatment groups.
We analysed the studies with reported pharmaceutical company
sponsorship separately for the outcome resolution of symptoms
post-treatment. Two studies that did not report funding sources
showed a statistically significant effect in favour of cephalosporins
(OR 0.47, 95% CI 0.27 to 0.81; ARD 0.02, NNTB 50; Carbon
1995; Disney 1992a). Pooling sponsored studies did not result in
a significant difference between antibiotic groups (Henness 1982-
study 1; Nemeth 1999; Reed 1991). See Analysis 1.9.
One trial in children (n = 138) also reported resolution of symp-
toms within 24 hours of treatment (Randolph 1985), and found
no difference between treatment groups (OR 0.97, 95% CI 0.34
to 2.74). See Analysis 1.3.
A sensitivity analysis revealed that in the ITT analysis, the trial by
Disney 1992a contributed to the heterogeneity of the analysis in
children. However, removing this trial from the analysis did not
result in a significant change in the overall outcome. In a similar
analysis for the evaluable patients only, the trial by Reed 1991
appeared to contribute most to the heterogeneity. After removing
this trial, the I² statistic was no longer important. Pooling the two
remaining trials in children showed a statistically significant benefit
in favour of cephalosporins in children. However, the overall effect
in all participants remained non-significant.
1.2. Secondary outcomes
1.2.1 Sore throat
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One trial in children found no difference between treatment
groups for resolution of sore throat (OR 0.97, 95% CI 0.23 to
4.04; n = 138; Analysis 1.4; Randolph 1985).
1.2.2 Fever
One trial in children found no difference between treatment
groups for resolution of fever (OR 0.97, 95% CI 0.19 to 4.98; n
= 138; Analysis 1.5; Randolph 1985).
1.2.3 Duration of illness
Not reported.
1.2.4 Incidence of relapse
In four trials (n = 1386) that reported the incidence of clinical
relapse in evaluated participants there was a benefit of treatment
with cephalosporins over penicillin in the total population (OR
0.55, 95% CI 0.30 to 0.99; ARD 0.02, NNTB 50; Carbon 1995;
Disney 1992a; Nemeth 1999; Reed 1991). This was due to a
difference in two trials in adults (OR 0.42, 95% CI 0.20 to 0.88;
ARD 0.03, NNTB 33.3, n = 770; Carbon 1995; Nemeth 1999).
There was no difference between trials in children (OR 0.89, 95%
CI 0.33 to 2.45; n = 616; Analysis 1.6; Disney 1992a; Reed 1991).
1.2.5 Incidence of complications
In one trial in adults no complications were reported in the
cephalosporin group (119 participants) or the penicillin group
(125 participants) (Carbon 1995).
1.2.6 Adverse events
Three trials in adults reported the incidence of adverse effects
(Carbon 1995; Nemeth 1999; Reed 1991). There was significant
heterogeneity among the trials. In the cephalosporin group, 212
of 788 participants reported adverse events, compared with 87
of 491 in the penicillin group. There was no difference between
treatments (OR 0.94, 95% CI 0.27 to 3.25; Analysis 1.8).
The reported adverse events were predominantly gastrointestinal
(diarrhoea, nausea and vomiting, constipation), but also vaginal
moniliasis and headaches have been reported with both antibiotic
classes (Carbon 1995; Nemeth 1999). Reed 1991 did not report
the nature of the adverse events. None of the adverse events were
serious. Carbon 1995 reported one patient with penicillin allergy.
2. Macrolide versus penicillin
Six trials contributed to the pooled analysis within this comparison
(Bachand 1991; Levenstein 1991;Norrby 2002;O’Doherty 1996;
Stein 1991; Watkins 1997). We assessed the overall quality of the
evidence for the primary outcome, resolutionof symptoms, and for
incidence of relapse and for adverse events as low. We downgraded
the quality due to unclear randomisation and blinding, and wide
confidence intervals (see Summary of findings 2).
2.1 Primary outcome: Resolution of symptoms post-
treatment
Five trials in adults (Bachand 1991; Levenstein 1991; Norrby
2002; Stein 1991;Watkins 1997), and one in children (O’Doherty
1996), investigated the resolution of symptoms at various points in
time post-treatment. In the ITT analysis of 1728 participants there
were no differences between the treatment groups (OR 1.11, 95%
CI 0.92 to 1.35; low quality evidence; Analysis 2.1; Summary of
findings 2). The estimate of effect in adults (OR1.07, 95%CI0.86
to 1.34; N = 5, n = 1239) was similar to children (OR 1.25, 95%
CI 0.85 to 1.84; n = 489). The analysis of evaluable participants
only did not result in any significant differences between treatment
groups (OR 0.79, 95% CI 0.57 to 1.09; n = 1159; low quality
evidence; Analysis 2.2; Summary of findings 2). The estimate for
the five trials in adults (n = 801) was OR 0.88, 95% CI 0.59 to
1.31, and one trial in children (n = 358) was OR 0.64, 95% CI
0.36 to 1.11.
ITT analysis of pharmaceutical industry sponsored trials versus
trials that did not report funding sources did not show significant
differences in results (Analysis 2.7).
2.2 Secondary outcomes
2.2.1 Sore throat
Two trials reported resolution of sore throat in adults, and found
no difference between the treatments (OR 0.97, 95% CI 0.64 to
1.46; n = 371; Analysis 2.3; Bachand 1991; Levenstein 1991).
2.2.2 Fever
Resolution of fever at two to 10 days post-treatment was re-
ported in two trials with 371 adult participants (Bachand 1991;
Levenstein 1991). All participants in both groups were free of fever
at the time they were evaluated (45 participants in the macrolide
group and 39 in the penicillin group; OR 1.05, 95% CI 0.69 to
1.59; Analysis 2.4).
2.2.3 Duration of illness
Not reported.
2.2.4 Incidence of relapse
Incidence of clinical relapse was evaluated in six trials; five trials
in adults (Bachand 1991; Levenstein 1991; Norrby 2002; Stein
1991; Watkins 1997), and one in children (O’Doherty 1996).
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Twenty-two of 441 participants in the macrolide group and 16
of 361 in the penicillin group reported relapse at day 15 to 56
post-treatment. The differencewas not statistically significant (OR
1.21, 95% CI 0.48 to 3.03; Analysis 2.5; Summary of findings 2).
2.2.5 Incidence of complications
Not reported.
2.2.6 Adverse events
In the six trials (n = 1727), five in adults and one in children (
O’Doherty 1996), that reported on the incidence of adverse events,
therewere no statistically significant differences between treatment
groups: 282 events were reported in the macrolide group and 251
in the penicillin group (OR 1.19, 95% CI 0.82 to 1.73; Summary
of findings 2). In the trial in children, macrolides seemed to cause
more adverse events than penicillin (OR 2.33, 95% CI 1.06 to
5.15; n = 489, NNTH 17.2; Analysis 2.6).
The reported adverse events were predominantly gastrointestinal
(diarrhoea, nausea and vomiting, constipation, abdominal pain),
but vaginal moniliasis and headaches and dizziness were also re-
ported with both antibiotic classes. Rash was reported in patients
taking penicillin (O’Doherty 1996). Most studies did not report
any serious adverse events, but Levenstein 1991 reported two se-
rious events - depression and balanitis.
3. Azithromycin versus amoxicillin
3.1 Primary outcome: Resolution of symptoms post-
treatment
One trial (unpublished data provided by Pfizer) studied the effect
of a single dose of azithromycin versus 10 days of amoxicillin in
673 children (NCT00643149). The clinical cure rate was reported
for the ’bacteriological per protocol population’ only, which was
defined as those with GABHS-positive culture within 48 hours
of treatment start, at least eight days of treatment (compliance)
and available data at baseline. Effects were measured at 24 to 28
days after commencing treatment and on days 38 to 42. In the
azithromycin group 239/245 participants achieved clinical cure at
the first evaluation point versus 218/237 in the amoxicillin group
(OR fixed-effect 0.29, 95% CI 0.11 to 0.73; NNTB 18; Analysis
3.2). The difference was not statistically significant in the ITT
analysis (OR 0.76, 95% CI 0.55 to 1.05; Analysis 3.1).
3.2 Secondary outcomes
3.2.1 Sore throat
Not reported.
3.2.2 Fever
Not reported.
3.2.3 Duration of illness
Not reported.
3.2.4 Incidence of relapse
Ondays 38 to 45 after treatment commencement, the per protocol
population was reduced to 223 in the azithromycin group and
199 in the amoxicillin group. The incidence of relapse did not
differ between groups in the ITT analysis (OR 0.75, 95% CI
0.55 to 1.02; Analysis 3.3) or the bacteriological per protocol
population (16/223 in the azithromycin group versus 16/199 in
the amoxicillin group; OR 0.88, 95% CI 0.43 to 1.82; Analysis
3.4).
3.2.5 Incidence of complications
Not reported.
3.2.6 Adverse events
In total, 57.5% of participants in the azithromycin group and
56.3% in the amoxicillin group reported experiencing an adverse
event. However, reported treatment-related adverse events were
more prevalent in the azithromycin group (27.6%) than in the
amoxicillin group (12.5%); (OR 2.67, 95% CI 1.78 to 3.99).
The most commonly reported adverse events were related to the
digestive system (diarrhoea, nausea, vomiting, abdominal pain)
and were more common in patients treated with azithromycin
(34.1%) than those treated with amoxicillin (16.1%). Rash was
more common in the amoxicillin group (3.0% versus 0.6% in
the azithromycin group). No deaths or serious adverse events were
reported (Analysis 3.5).
4. Carbacephem versus penicillin
Three trials were included in this comparison (n = 795): one in
children (Disney 1992b), one in adults (McCarty 1992a), and one
in a mixed population of adults and children (but predominantly
adults; 90% were aged over 12 years) (Muller 1992).
4.1 Primary outcome: Resolution of symptoms post-
treatment
In the ITTanalysis,more participants reported resolutionof symp-
toms in the carbacephem group than in the penicillin group (OR
for absence of symptom resolution post-treatment 0.70, 95% CI
0.49 to 0.99; n = 795, ARD 0.07, NNTB 14.3; Analysis 4.1).
There was no difference in adults (OR 0.75, 95%CI 0.46 to 1.22;
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n=562); in children therewas a beneficial effect fromcarbacephem
(OR 0.57, 95% CI 0.33 to 0.99; n = 233, ARD 0.12, NNTB
8.3). The analysis of evaluable participants showed no differences
between treatment groups (OR 0.62, 95% CI 0.38 to 1.01; n =
602; Analysis 4.2).
4.2 Secondary outcomes
4.2.1 Sore throat
Not reported.
4.2.2 Fever
Not reported.
4.2.3 Duration of illness
Not reported.
4.2.4 Incidence of relapse
There were no differences in the incidence of clinical relapse be-
tween groups treated with carbacephem or penicillin (21 events
in 267 participants treated with carbacephem and 16 in 256 par-
ticipants treated with penicillin; OR 1.27, 95% CI 0.64 to 2.50;
Analysis 4.3).
4.2.5 Incidence of complications
Not reported.
4.2.6 Adverse events
There were no differences in reported adverse events between treat-
ments (75 events reported in 396 participants treated with car-
bacephem and 71 in 399 participants treated with penicillin; OR
1.08, 95%CI 0.75 to 1.55). Muller 1992 reported that one partic-
ipant was hospitalised for surgical drainage of a tonsillar abscess in
the group treated with loracarbef one day after initiating therapy.
See Analysis 4.4.
Reported adverse events were predominantly gastrointestinal (di-
arrhoea, nausea, vomiting) in all treatment groups. Headaches
were reported in McCarty 1992a and Muller 1992, and vaginal
moniliasis in McCarty 1992a. Rashes were reported in both treat-
ment groups (Disney 1992b; Muller 1992).
5. Clindamycin versus ampicillin
Jackson 1973 compared treatment with clindamycin to ampicillin
(n = 314). The only clinical outcome reported was adverse events.
5.1 Primary outcome: Resolution of symptoms post-
treatment
Not reported.
5.2 Secondary outcomes
5.2.1 Sore throat
Not reported.
5.2.2 Fever
Not reported.
5.2.3 Duration of illness
Not reported.
5.2.4 Incidence of relapse
Not reported.
5.2.5 Incidence of complications
Not reported.
5.2.6 Adverse events
Six participants reported adverse events in the group treated with
clindamycin (156 participants) and 14 participants experienced
adverse events in the ampicillin group (158 participants). The
difference was not statistically significant (OR 0.41, 95% CI 0.15
to 1.10; Analysis 5.1). Gastrointestinal adverse events (nausea or
vomiting and loose stools) and rash or urticaria occurred in both
treatment groups. No other events were reported.
6. Sulphonamide versus penicillin
One trial in adults was included in this comparison (Trickett
1973). It reported only on adverse events.
6.1 Primary outcome: Resolution of symptoms post-
treatment
Not reported.
6.2 Secondary outcomes
6.2.1 Sore throat
Not reported.
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6.2.2 Fever
Not reported.
6.2.3 Duration of illness
Not reported.
6.2.4 Incidence of relapse
Not reported.
6.2.5 Incidence of complications
Not reported.
6.2.6 Adverse events
Trickett 1973 reported eight events in participants treated with
sulphonamides and six events in the penicillin group; Analysis 6.1.
They found no difference between sulphonamide and penicillin
(OR 1.37, 95% CI 0.43 to 4.34). Gastrointestinal disturbances,
rash, (reversible) leukopenia and (reversible) liver and kidney func-
tion disturbances were reported in both treatment groups.
Penicillin allergy
We assessed the reporting of penicillin allergy in all included stud-
ies. Carbon 1995 reports one patientwith a ’severe allergic reaction’
in the penicillin group, but no further details are provided. Muller
1992 reported that one patient developed a rash and another expe-
rienced vomiting, both attributed to use of penicillin (although pa-
tients were then successfully switched to amoxicillin/clavulanate).
However, in the loracarbef group, also one participant discontin-
ued treatment because of a rash. Trickett 1973 reports one patient
with a rash in the penicillin group, but two patients reported a rash
in the trimethoprim/sulfamethoxazole group. None of the other
studies included in this review specifically report penicillin allergy.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Macrolides compared to penicillin for group A streptococcal pharyngitis
Patient or population: group A streptococcal pharyngit is
Settings: outpat ients
Intervention: macrolide
Comparison: penicillin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Penicillin Macrolide
Resolut ion of symp-
toms post-treatment
(ITT analysis)
Study populat ion OR 1.11
(0.92 to 1.35)
1728
(6 RCTs)
⊕⊕©©
LOW1,2
423 per 1000 448 per 1000
(402 to 497)
Moderate
426 per 1000 451 per 1000
(405 to 500)
Resolut ion of symp-
toms post-treatment
(evaluable part icipants
only)
Study populat ion OR 0.79
(0.57 to 1.09)
1159
(6 RCTs)
⊕⊕©©
LOW1,2
172 per 1000 141 per 1000
(106 to 185)
Moderate
161 per 1000 131 per 1000
(98 to 173)
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Incidence of
relapse (evaluable par-
t icipants)
Study populat ion OR 1.21
(0.48 to 3.03)
802
(6 RCTs)
⊕⊕©©
LOW1,2
44 per 1000 53 per 1000
(22 to 123)
Moderate
109 per 1000 129 per 1000
(56 to 271)
Adverse events (ITT
analysis)
Study populat ion OR 1.19
(0.82 to 1.73)
1727
(6 RCTs)
⊕⊕©©
LOW1,2
324 per 1000 363 per 1000
(282 to 453)
Moderate
286 per 1000 323 per 1000
(248 to 410)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; ITT : intent ion-to-treat; OR: odds rat io; RCT : randomised controlled trial.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Unclear randomisat ion.
2Wide conf idence intervals.
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D I S C U S S I O N
Summary of main results
Our meta-analysis found generally low quality evidence (as per
the GRADE assessment) that did not show clinically important
differences in clinical outcomes when different classes of antibi-
otics were compared with penicillin in adults and children with
pharyngitis caused by GABHS.
Resolution of symptoms
ITT analysis did not show any difference in resolution of symp-
toms between cephalosporins and penicillin. When only evalu-
able participants were included in the analysis (i.e. participants for
whom an outcome was known) there seemed to be a benefit of
cephalosporins over penicillin with regard to resolution of symp-
toms after treatment (number needed to treat to benefit (NNTB)
20). Subgroup analysis of adults and children (aged between one
month and 17 years) did not reveal any significant differences, but
this could be attributed to lack of sufficient power.
ITT analysis of carbacephem versus penicillin showed a benefit of
carbacephem with regard to resolution of symptoms after treat-
ment (NNTB 14.3). There was no significant benefit in the (large)
adult subgroup, and the effect may be largely based on an ob-
served effect in children (aged between six months and 12 years)
(NNTB 8.3). The analysis of evaluable participants only did not
reach statistical significance (but the estimated NNTB was likely
to be high).
Pooling of trials comparing macrolides with penicillin did not
result in any differences between groups in terms of resolution of
symptoms. Only one unpublished trial in children aged between
two and 12 years that compared a single dose of azithromycin with
10 days of amoxicillin found that more children on azithromycin
were cured after 24 to 28 days than with amoxicillin. However,
this effect was no longer significant in the ITT analysis.
Other comparisons with penicillin
(clindamycin or sulphonamides) did not report clinical outcomes
for this meta-analysis.
Relapse
The incidence of relapse in evaluable participants seemed to be
lower in participants treated with cephalosporins compared with
penicillin, but the event rate was low (approximately 3.5%) and
the NNTB quite high (NNTB 50). There were no differences in
relapse rate between other antibiotics and penicillin.
Adverse events
Adverse events occurred at a similar rate in all treatment groups,
except children treated withmacrolides, who seemed to experience
more adverse events than children treatedwith penicillin (although
this difference was not statistically significant, most likely due to
insufficient power) or amoxicillin or ampicillin.
The results of our meta-analysis need to be considered in the con-
text of morbidity (including serious complications) prevalence,
concerns about rising antibiotic resistance, and economic con-
straints in all healthcare systems.
Penicillin allergy
Incidence of penicillin allergy was poorly if at all reported in the
included trials. When a rash is reported in the penicillin group
this is often also reported in the comparator group. The limited
information about penicillin allergy may reflect the low incidence
in the general population. Albin 2014 found that penicillin al-
lergy was reported in 11.5% of patients in a retrospective chart
review, but only 11.8% of those with a documented allergy had
experienced an anaphylactic reaction. The incidence of true ana-
phylaxis has been reported as less than 0.01% (Battacharya 2010).
It is also possible that patients with known penicillin allergies were
excluded from the trials resulting in a low incidence of allergies
during the trial. This exclusion was only explicitly mentioned in
a few of the included studies.
Overall completeness and applicability of
evidence
Although we searched several databases and scrutinised all refer-
ences listed in identified reviews and publications of trials, we may
have missed some trials. We contacted experts and pharmaceutical
companies. One pharmaceutical company responded, but this did
not result in additional data. An updated search in 2012 identified
an unpublished study, and a report was provided by the manu-
facturer in 2013 (NCT00643149). This study was included in
the 2014 update but we did not identify any new published or
unpublished trials in a new search. As an analysis of unpublished
data used in Cochrane Reviews suggested that searching for un-
published data generally does not uncover new data that are im-
portant to the conclusion of the review (van Driel 2009), the lack
of further unpublished data may not have had an important im-
pact on the results of our review.
Our meta-analysis focused on clinical outcomes. Reviews that
report bacteriological outcomes point to the superiority of
cephalosporins over penicillin with regard to eradication of
GABHS (Brunton 2006;Casey 2004).However, this does not take
clinical presentation into account. Gerber 1999a found no differ-
ence in bacteriologic treatment success rates between cefadroxil
and penicillin groups among participants classified clinically as
likely to have trueGABHSpharyngitis, but cephalosporins seemed
to be more successful in eradicating GABHS in patients classified
as clinically likely to be streptococcal carriers. Contamination of
treatment groups by such chronic GABHS carriers contributes to
the apparent superiority of cephalosporins in studies focusing on
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bacteriological outcomes (Shulman 2004); this is of very limited
clinical relevance. To our knowledge, chronic streptococcal car-
riage is not linked to higher risk of developing GABHS pharyngi-
tis, and hence eradication of streptococci in carriers is not a treat-
ment goal. Information on complications is scarcely reported and
therefore we could not draw any conclusions concerning this out-
come.
Our review included studies involving children and adults, but age
ranges of participants in each study varied widely, and there was
significant overlap.Therefore, it was not always possible to perform
subgroup analyses based on age groups. It was not possible to
draw conclusions about specific age groups. This would have been
clinically relevant because GABHS is more common in children
aged between five and 15 years (Worrall 2007).
Quality of the evidence
A strength of our review is that we included only randomised
and double-blinded trials. This was intended to minimise risk of
bias related to participant selection and reporting of outcomes.
However, in spite of the lower risk of bias due to methodology,
reporting of findings and transparency of analyses in the trials were
often unsatisfactory. Patient characteristics were poorly reported
and outcomes, poorly, or not at all defined. Dropout rates in some
studies were very high (> 20%).
The overall risk of bias in included studies was difficult to assess
because the process of randomisation and blinding was not de-
scribed in most studies. For instance, only four studies described
the method used to conceal allocation (Jackson 1973; Randolph
1985; Reed 1991; Watkins 1997).
It is surprising that resolution of sore throat, a key symptom in
GABHS pharyngitis and important reason for patients to consult
their doctor (van Driel 2006), was only reported as a separate out-
come in one study (McCarty 1992a). Most studies however, as-
sessed our primary outcome which is a composite endpoint con-
sisting of a combination of symptoms including sore throat, fever,
and feeling unwell. This is of course also of clinical relevance to
patients.
The overall quality of the pooled evidence assessed with the
GRADE tool was low for all outcomes in the comparison of
macrolides versus penicillin and low or very low for the compari-
son cephalosporins versus penicillin. We downgraded the quality
of evidence mainly because of lack of, or poor reporting of ran-
domisation, or blinding, or both, heterogeneity and wide confi-
dence intervals.
Potential biases in the review process
Pooling of outcomes was hampered by differences in outcome
definitions among studies. Because most trials measured clinical
outcomes within two weeks of the end of antibiotic treatment,
they were pooled for the outcome resolution of symptoms post-
treatment. The trial that reported symptom resolution within the
first 24 hours of treatment was considered separately. Very few
trials reported on specific symptoms related to acute GABHS ton-
sillopharyngitis. Because symptom resolution is a subjective out-
come, the interpretation may differ among trials, and pooling may
therefore be inappropriate. However, differences between compar-
ison groups in the same trial were not affected because they were
measured in the same population.
We used ITT analysis of the selected outcomes for our meta-anal-
yses. However, this may have underestimated the efficacy of treat-
ment. Most trials reported numbers of participants randomised,
but included only the evaluated participants in the outcome anal-
ysis. When reported, a common reason for post-randomisation
exclusion was negative throat culture, suggesting that another
pathogen caused the signs and symptoms of acute tonsillopharyn-
gitis. Including these GABHS-negative participants in the analysis
could bias the results if exclusion was not similar in both treatment
groups. Some trials reported exclusions per group and show that
this is not the case. When comparing two efficacious treatments
this potential underestimation did not seem relevant because it
did not influence conclusions. However, for trials that did not re-
port this, it was not possible to know if selective exclusions oc-
curred. We checked if the analysis method influenced outcomes
by performing both ITT and analysis of evaluable participants for
the outcome resolution of symptoms post-treatment. This showed
different results in two comparisons. When cephalosporins and
penicillin were compared, ITT analysis yielded a non-significant
result, whereas analysis of evaluable participants showed a ben-
efit of cephalosporins over penicillin. The opposite occurred in
the analysis of effect on the same outcome in participants treated
with carbacephem versus penicillin; where ITT analysis showed
a statistically significant difference and the evaluable participants
analysis did not, most likely due to a reduction in the number of
participants included in the analysis (resulting in reduced statis-
tical power). Analysing only evaluable participants implies a high
risk of bias as there may have been a selective dropout. On the
other hand, the ITT analysis can be considered as a conservative
estimate of the true effect.
The estimated odds ratios (ORs) suggested that large benefits could
be expected when treating patients with cephalosporins or carba-
cephems. However, these supposedly impressive effects expressed
as a relative measure of risk (ORs) do not always translate into a
clinically meaningful difference. For example, the estimated OR
of 0.55 for the incidence of relapse in cephalosporins compared
with penicillin, suggests that the risk of relapse could be halved
by treating patients with cephalosporins. However, the associated
absolute risk difference is 0.02, resulting in a NNTB of 50, which
means that 50 patients need to be treated with broad-spectrum,
more expensive antibiotics to prevent one additional relapse.
Calculating the absolute risk difference and theNNTB is therefore
a useful method to assess the clinical importance of a relative risk.
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The interpretation of the NNTBs (how many patients needed
to treat is acceptable) is, however, not clear-cut and depends on
assessment of benefit and harm and also cost-effectiveness.
All trials in our review were performed in high-income countries.
The incidence of suppurative and other complications (which are
rare in high-income countries), as well as antimicrobial resistance
rates, may be different in low-income countries or specific commu-
nities with high prevalence of GABHS tonsillitis (Hanna 2010).
Therefore, studies performed in low-income and high-prevalence
communities are needed.
Agreements and disagreements with other
studies or reviews
We found that although there seems to be some benefit of antibi-
otics with a wider spectrum, such as cephalosporins and carba-
cephem, this observed effect is not consistent across analysis meth-
ods and subgroups. Cephalosporins showed benefit regarding res-
olution of symptoms only in the analysis of evaluable participants,
and carbacephem is superior to penicillin for this outcome only
in the ITT analysis (attributable to an effect in children treated
with a carbacephem). The NNTBs associated with the observed
effects were relatively high (20 for treatment with cephalosporins
compared with penicillin), except perhaps for the effect of carba-
cephem in children (NNTB 8.3). There was no clinically mean-
ingful difference between penicillin and the other classes of an-
tibiotics studied with regard to rate of clinical relapse. However,
cephalosporins seemed to reduce the relapse rate (NNTB 50), es-
pecially in adults (NNTB 30).
The effects observed in cephalosporins and carbacephems and not
in the other antibiotic classes can be explained by the fact that
although they are considered different classes of antibiotics, car-
bacephems chemically closely resemble cephalosporins (Cooper
1992).
Unpublished study, NCT00643149, concluded that a single dose
of azithromycin was superior to 10 days of amoxicillin in children.
However, the analysis was based on a per protocol population that
had completed at least eight days of treatment. Results were based
on those patients who responded bacteriologically, thus censoring
patients with strains resistant to the allocated antibiotic. Because
eradication rates were higher in the azithromycin arm this may
have biased the analysis. The ITT analysis, which underestimates
the effect, did not show any difference between groups. In addi-
tion, amoxicillin may not be an appropriate choice for the treat-
ment of GABHS pharyngitis/tonsillitis, considering the implica-
tions of using wide spectrum antibiotics on resistance in the com-
munity.
Interpretation of these findings for clinical practice is not straight-
forward. One could argue that our meta-analysis points to a supe-
rior efficacy of cephalosporins over penicillin, especially in adults
where the upper limit of the 95% confidence interval (CI) is 1.01
(P = 0.06) in the ITT analysis. The population size may not have
been large enough to reach statistical significance. This finding
is in line with an earlier review concluding that cephalosporins
are superior to penicillin in treating GABHS pharyngitis, and
therefore cephalosporins should be considered first choice (Casey
2004). However, in our review the absolute difference between the
cephalosporin or penicillin, although not statistically significant,
was 2.5%, which implies a NNTB of 40. Treating 40 patients
with cephalosporins instead of penicillin would incur additional
costs to healthcare systems and add to the risk of developing an-
tibiotic resistance, especially in broad-spectrum antibiotics such
as cephalosporins.
The observed superior effect of cephalosporins in reducing the rate
of relapse has been reported elsewhere (Casey 2004). However,
in our review it is only observed in adults and may be biased by
the rather liberal definition of relapse in the study that accounts
for 49% of weighting in the meta-analysis (Nemeth 1999); “wors-
ening of, or absence of significant remission of, signs and symp-
toms 17 to 24 days post-therapy or need for further AB therapy”,
whereas in other studies “recurrence of symptoms” after initial re-
mission was required. The NNTB of 33 participants that need to
be treated with cephalosporins rather than penicillin to prevent
one participant experiencing relapse illustrates the limited clinical
relevance of this statistically significant result.
How can the differences between Casey’s meta-analysis and ours
be explained? Casey 2004 included 35 trials; two-thirds were not
blinded and reporting of randomisation and losses to follow-up
was very poor, implying a high risk of bias (Gerber 2004). By
restricting inclusion to double-blinded trials we ruled out one
source of potential bias and improved methodological rigour. The
Casey 2004 subgroup analysis of double-blinded studies gener-
ated an OR similar to ours (although with a much narrower CI:
OR 0.43, 95% CI 0.25 to 0.71), but included studies with carba-
cephems, which have been advertised as a separate class of antibi-
otics (Cooper 1992). Casey 2004 reported an analysis of evalu-
able patients, whereas ITT analysis may be more appropriate es-
pecially with important numbers of dropouts (which is the case
in many of the trials included in our review). The trial popula-
tions included in Casey 2004, as in ours, may have been contami-
nated with chronic carriers of GABHS who had intercurrent viral
pharyngitis (Gerber 2004), but it was not clear if this has implica-
tions for clinical practice. Gerber 1999b argued that the superior
effectiveness of cephalosporins over penicillin observed in some
studies may reflect a greater ability to eradicate the streptococcal
carrier state rather than actual superior effectiveness of “bona fide
acute GABHS pharyngitis”.
We found no differences in the incidence of adverse events, and
data on long-term follow-up and occurrence of complicationswere
insufficient. Therefore, costs and antimicrobial resistance patterns
are important in making treatment choices.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review did not find clinically important differences in clini-
cal outcomes when different classes of antibiotics were compared
with penicillin in adults and children with pharyngitis caused
by GABHS. The finding that carbacephems and cephalosporins
may have some benefit over penicillin in terms of resolution of
symptoms and incidence of relapse was inconsistent across analy-
sis methods (only statistically significant for the evaluable patients
analysis) and the NNTB was substantial. This is not compelling
evidence to alter current guideline recommendations for treatment
of patients with GABHS tonsillopharyngitis. Moreover, we found
no clinically important differences in occurrence of adverse events,
and data on the incidence of complications were too few to draw
conclusions.
Antibiotics have a limited effect in the treatment of patients with
acute sore throat, even in the presence of GABHS. However, if
antibiotics are to be prescribed, based on these results and taking
into consideration the costs and antimicrobial resistance patterns
of different antibiotics, penicillin can still be considered a first
choice treatment for both adults and children.
Implications for research
The observed differences in clinical efficacy between adults and
children needs further exploration. The currently available studies
include different age ranges whichmakes it difficult to identify dif-
ferential effects in various age groups. Individual patient data were
unavailable; therefore, future studies reporting effects in distinct
age groupsmay provide clinically relevant information. Prevention
of serious complications such as acute rheumatic fever and acute
glomerulonephritis are often mentioned as arguments in favour
of antibiotic use. However, the current data do not provide infor-
mation about the impact of different antibiotics for prevention of
complications. Further studies with longer follow-up may be able
to address this issue. Because these complications seem to be more
prevalent in low-income and high-risk communities (for exam-
ple, Australian Indigenous communities), studies in these specific
high-risk communities are needed. Economic analysis of the cost-
effectiveness of different treatment optionsmay provide additional
guidance for making treatment choices.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bachand 1991
Methods - RCT, randomised 1:1
- Double-blinded
- Double-dummy
Participants - Number of randomised participants: 128 (108 S. pyogenes positive)
- Number of participants evaluated: 90
- Number of dropouts: 38 (29.7%)
- Setting: 17 clinical centres US
- Age: 12 to 62 years
- Diagnosis: rapid immunoassay test, throat culture
- Inclusion criteria: confirmed GABHS pharyngitis
- Exclusion criteria: risk for pregnancy or lactation, weight < 34 kg, no sore throat
with at least one sign of streptococcal pharyngitis, negative rapid immunoassay test,
overall poor health, hypersensitivity to erythromycin or penicillin, renal impairment or
hepatic disease, history of rheumatic fever or cardiac valvular disease, rash suggestive of
scarlet fever, active eye inflammation, treated with systemic antibiotic within 2 weeks/an
investigational drug within four weeks/long-acting injectable penicillin within six weeks
prior to trial, concurrent antimicrobial agents
Interventions - Groups: clarithromycin, 250 mg (2 x 125 mg) caps 12-hourly (n = 65); penicillin VK
250 mg (2 x 125 mg) caps 6-hourly (n = 63)
- Duration of therapy: 80% > 10 days
- Duration of follow-up: 15 to 56 days
Outcomes - Clinical outcomes at 2 to 10 days post-treatment: cure (pre-treatment signs and symp-
toms resolved and pathogen eradicated); improvement (pre-treatment signs and symp-
toms improved but not resolved); failure (pre-treatment signs and symptoms not im-
proved or worsened and pathogen persisted); indeterminate (response could not be as-
signed); relapse/recurrence (pre-treatment signs and symptoms resolved but reappeared
and pathogen recurred)
- Relapse at 15 to 56 days post-treatment
- Adverse effects
- Bacteriological outcomes
- Serology
Notes - Funding: not reported, but author is employee of Abbott International Ltd.
- Ethics approval: “the protocol was approved by local ethics committees”
- No ITT for efficacy reported
- No ITT reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Bachand 1991 (Continued)
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised (1:1)”. Not de-
scribed how sequence was generated
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “To maintain the double-blind nature of
the study, placebos were administered and
all drugs were placed in identical grey
opaque capsules.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 26 participants prematurely discontinued
and 38 were excluded from efficacy analysis
(reasons reported)
29.7% post-randomisation dropout
No ITT analysis (128 randomised and 90
included in efficacy analysis)
Selective reporting (reporting bias) Unclear risk “There was no evidence of investigator bias
in any of the analyses.”
Other bias High risk Funding: not reported, but author is em-
ployee of Abbott International Ltd
Carbon 1995
Methods - RCT
- Double-blinded
- Double-dummy
Participants - Number of participants enrolled: 250
- Number of participants randomised: 240
- Number of participants evaluated: 236
- Number of dropouts: 4 (2%)
- Setting: 60 French General Practice clinics
- Age: > 15 yrs
- Diagnosis: rapid antigen test, throat culture
- Inclusion criteria: fever =/> 38 °C, odynophagia, erythema or purulent exudate of
pharynx, at least one tender submaxillary lymph node, rapid antigen test positive for
GABHS, followed by positive throat culture
- Exclusion criteria: allergy to beta-lactams, pregnancy, lactation, chronic tonsillitis, an-
tibiotics in 5 days preceding randomisation, no written consent
Interventions - Groups: cefotiam hexetil (CTM), 200 mg twice a day for 5 days and a penicillin V
(PEV)-like placebo three times a day for 10 days (n = 119); penicillin V (PEV) megaunit
(600 mg) three times a day for 10 days and CTM-like placebo twice a day for 5 days (n
= 125)
- Duration of treatment: 15 days
- Duration of follow-up: 90 days
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Carbon 1995 (Continued)
Outcomes - Clinical outcomes: success = cure (complete resolution of fever and symptoms) on days
10 and 30 or improvement on day 10 and cure on day 30 without further antibiotics)
- Failure = no response to therapy on day 10, or improvement on day 10 but required
further antibiotic or relapsed (recurrence of fever and/or symptoms), or cured on day 10
but subsequent relapse
- Relapse assessed on day 90
- Adverse effects
- Bacteriological outcomes
Notes - Funding: not reported
- Ethics approval: not mentioned
- Described as ITT analysis for efficacy, but post-randomisation exclusions not included
in analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised”, but no descrip-
tion of randomisation sequence
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Reported as “double
blind, double dummy”, but no description
of how blinding of different administration
frequency and duration was maintained
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts: 4 lost to follow-up (all in peni-
cillin group).
no ITT analysis (although reported in table
that ITT, the numbers do not correspond
to ITT)
Selective reporting (reporting bias) Unclear risk Only clinical success reported, no specific
symptoms;
Adverse events reported, but no ITT anal-
ysis. 3 participants in each group discon-
tinued because of adverse events
Other bias Unclear risk Funding: not reported
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Disney 1992a
Methods - RCT
- Double-blinded
Participants - Number of participants eligible: 654
- Number of participants randomised: 525
- Number of participants evaluated: 525
- Number of dropouts: not specified
- Setting: 7 paediatric practices in US
- Age: 4 to 17 yrs
- Diagnosis: clinical tonsillitis or pharyngitis, throat cultures
- Inclusion criteria: clinical tonsillopharyngitis and throat cultures strongly positive for
GABHS
- Exclusion criteria: concurrent enrolment of siblings, 2 ormore sore throats in previous 6
months, treated with antibiotic in previous 2 weeks, throat culture negative for GABHS
Interventions - Groups: cephalexin 27 mg/kg 4 times per day (n = 263); penicillin 27 mg/kg 4 times
per day (n = 262)
- Duration of treatment: 10 days
- Duration of follow-up: 32 to 35 days
Outcomes - Clinical outcomes: clinical failure (not defined) at 32 to 35 days
- Clinical relapse (new infection with different serotype)
- Bacteriological outcomes
- Antistreptolysin-O titres
- Anti-DNase B titres
Notes - Funding: grant from Lilly Research Laboratories, Indianapolis, Ind., US
- Ethics approval: not mentioned
- ITT analysis on 525 participants completing the protocol, no information on dropouts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised”, but no description of randomi-
sation sequence
Allocation concealment (selection bias) Unclear risk “The participants were assigned...on a random schedule sup-
plied by Eli Lilly and Co.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “...the physician and parents were not appraised as to who
was in which group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No description of dropouts, 525 of 525 randomised patients
reported
ITT analysis for clinical outcome.
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Disney 1992a (Continued)
Selective reporting (reporting bias) Unclear risk Only clinical (and bacteriological) failure reported, no symp-
toms specified.
No reporting of adverse events.
Other bias High risk Funding: grant fromLilly Research Laboratories, Indianapo-
lis, Ind., US
Disney 1992b
Methods - RCT, randomised 1:1
- Double-blinded
- Double-dummy
Participants - Number of participants enrolled: 233 (19 negative culture)
- Number of evaluated participants: 192
- Number of dropouts: 31 (13%)
- Setting: 11 paediatric offices in US
- Age: 6 months to 12 years
- Diagnosis: rapid antigen test, throat culture
- Inclusion criteria: clinical diagnosis of acute streptococcal pharyngitis/tonsillitis, in-
flammation and swelling, with or without fever =/> 38°C or exudate, rapid antigen test
or throat culture positive for GABHS, history of compliance
- Exclusion criteria: history of renal impairment (serum creatinine ≥177 µmol/L, 2.
0 mg/dL), any condition that could preclude evaluation of response, requirement for
systemic antibiotic, any antibiotic therapy within 3 days of start, hypersensitivity to
penicillins and/or cephalosporins
Interventions - Groups: loracarbef oral suspension, 15 mg/kg/day 2 divided doses, or 200 mg caps 2
per day (patient > 25 kg) (n = 120); penicillin VK oral suspension 20 mg/kg/day 4 doses,
daily max. 500 mg or 250 mg caps 4 per day (patient > 25 kg) (n = 113)
- Duration of treatment: 10 days
- Duration of follow-up: 4 to 5 weeks
Outcomes - Clinical outcomes at 3 to 5 days post-treatment: cure (absence of presenting signs/
symptoms); significant improvement (persistence of signs/symptoms); failure (insignifi-
cant change in signs/symptoms); relapse (recurrence of one or more signs/symptoms)
- Relapse at 5 to 6 weeks post-treatment
- Adverse effects
- Bacteriological outcomes
Notes - Funding: Eli Lilly Company
- Ethics approval: not mentioned
- No ITT reported for efficacy, but ITT for adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
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Disney 1992b (Continued)
Random sequence generation (selection
bias)
Unclear risk Reported as ”randomised (1:1), but no re-
porting of randomisation sequence
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Placebo was administered twice daily to
the loracarbef group to maintain double
blind conditions.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “unevaluable”: 16 in loracarbef group and
25 in penicillin group (negative pre-ther-
apy culture, insufficient therapy, incom-
plete data, lost to follow-up, late for visit,
concomitant use of other antibiotic).
No ITT for clinical outcome.
Selective reporting (reporting bias) Unclear risk ITT for adverse events.
Other bias High risk Funding: Eli Lilly Company
Henness 1982
Methods Study 1:
- RCT
- Double-blinded
Study 2:
- RCT, randomised
- Double-blinded
Participants Study 1:
- Number of participants randomised: 214 (47 no S.pyogenes)
- Number of evaluated participants: 162 (75.7%)
- Number of dropouts: 3 lost to follow-up from evaluable participants
- Setting: private paediatric practices in US
- Age: 1 to 16 yrs
- Diagnosis: throat culture
- Inclusion criteria: acute untreated tonsillopharyngitis
- Exclusion criteria: not reported
Study 2:
- Number of participants randomised: 198
- Number of evaluated participants: 198
- Number of dropouts: 0?
- Setting: private paediatric practices in US
- Age: 1 to 16 years
- Diagnosis: throat culture
- Inclusion criteria: acute untreated tonsillopharyngitis
- Exclusion criteria: not reported
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Henness 1982 (Continued)
Interventions Study 1:
- Groups: penicillin V suspension 8 mg/kg every 6 hours (n = 114); cefadroxil suspension
15 mg/kg twice daily (n = 100)
- Duration of treatment: 10 days
- Duration of follow-up: 27 to 43 days
Study 2:
- Groups: penicillin V suspension 10 mg/kg every 8 hours (n = 50); cefadroxil suspension
15 mg/kg twice daily (n = 50); erythromycin 15 mg/kg orally twice daily (n = 49); benza-
thine penicillin G (900,000 U) and procaine penicillin (300,000 U) once intramuscular
- Duration of treatment: 10 days for all oral treatments
- Duration of follow-up: 27 to 43 days
Outcomes Study 1:
- Clinical outcomes: cure (clinical improvement within first 24 hours of therapy and all
follow-up cultures no S.pyogenes); failure (illness consistent with streptococcal infection
and positive throat culture at 4 days post-therapy); carrier (asymptomatic with same type
S. pyogenes in throat culture obtained between 5 to 33 days post-therapy)
- Bacteriological outcomes
- Complete blood counts
- Urinalysis
- Streptozyme titres
- Susceptibility studies
Study 2:
- Clinical outcomes: not reported
- Bacteriological outcomes
- Streptozyme titres
- Susceptibility
Notes Study 1:
- Funding: not mentioned, author employee of Mead Johnson Pharmaceutical Division,
Evansville, US
- Ethics approval: not mentioned
- First study in the publication
- No ITT reported
Study 2:
- Funding: not mentioned, author employee of Mead Johnson Pharmaceutical Division,
Evansville, US
- Ethics approval: not mentioned
- Second study in the publication
- No ITT reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study 1:
Reported as “randomised”, but no descrip-
tion of randomisation sequence
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Henness 1982 (Continued)
Study 2:
Reported as “randomised”, but no descrip-
tion of randomisation sequence
Allocation concealment (selection bias) Unclear risk Study 1:
“...participants were assigned randomly...”
Study 2:
Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Study 1:
Reported as “double blind”, but no descrip-
tion of blinding.
Study 2:
Reported as “double blind”, but no descrip-
tion of blinding.
Incomplete outcome data (attrition bias)
All outcomes
High risk Study 1:
52 participants discontinued (cefadroxil 35
and penicillin 17); reasons: negative culture
(total 47; cefadroxil 31 and penicillin 16),
lost to follow-up (total 3; cefadroxil 2 and
penicillin 1), other (total 2; cefadroxil 2 and
penicillin 0)
24.3% post-randomisation dropout
No ITT analysis for clinical outcomes.
Study 2:
No dropouts described; according to re-
ported numbers no participants dropped
out
Selective reporting (reporting bias) Unclear risk Study 1:
Only clinical (and bacteriological) cure re-
ported, no specific symptoms; no ITT.
Adverse events not reported.
Study 2:
No clinical outcomes reported.
Other bias High risk Author is employee ofMead Johnson Phar-
maceutical Division, Evansville, US
Jackson 1973
Methods - RCT
- Double-blinded
Participants - Number of participants randomised: 314 (95 negative culture excluded from analysis)
- Number of participants evaluated: 207 (70%)
- Number of dropouts: 12 reported
- Setting: not described
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Jackson 1973 (Continued)
- Age: not described
- Diagnosis: throat culture
- Inclusion criteria: child in weight range 11.4 to 45.4 kg, pharyngitis, positive culture
or white blood count > 10,000
- Exclusion criteria: allergy to penicillin or lincomycin, received any antibiotics within
previous 6 weeks
Interventions - Groups: clindamycin daily dose 150 to 450 mg (n = 156); ampicillin daily dose 750
to 2000 mg (n = 158)
- Duration of treatment: 10 days
- Duration of follow-up: 26 to 28 days post-therapy
Outcomes - Adverse effects
- Bacteriological outcomes
Notes - Funding: Upjohn Company
- Ethics approval: not mentioned
- ITT for adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised”, but no description of randomi-
sation sequence
Allocation concealment (selection bias) Low risk “Labels for each group were randomised, sealed in sequen-
tially numbered envelopes,...”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
High risk 95 negative cultures excluded after randomisation; 12 posi-
tive cultures excluded due to failure to return first follow-up
culture (C7 and A5)
30% post-randomisation dropout
Selective reporting (reporting bias) Unclear risk Only clinical outcome for post-streptococcal sequelae.
ITT for adverse events.
Other bias High risk Funding: Upjohn Company
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Levenstein 1991
Methods - RCT
- Double-blinded
- Double-dummy
Participants - Number of participants enrolled: 243 (82 S. pyogenes negative)
- Number of participants evaluated in clinical outcome analysis: 125 (51.4%)
- Number of dropouts: 28 (12%)
- Setting: multicenter (Australia, New Zealand, Chile, South Africa) outpatient clinics
- Age: 13 to 59 years
- Diagnosis: rapid antigen test, throat culture
- Inclusion criteria: body weight =/> 50 kg, ability to swallow capsules, sore throat with at
least one other sign of streptococcal pharyngitis (pharyngeal erythema/exudate, cervical
lymph node tenderness, fever), positive rapid immunoassay for GABHS antigen
- Exclusion criteria: hypersensitivity to erythromycin or penicillin, previous course clar-
ithromycin or penicillinVK in this trial, renal impairment or history of glomerulonephri-
tis, history of hepatic disease or liver enzyme elevation, history of cardiac valvular disease,
rash symptomatic of scarlet fever, history of allergies and/or asthma
Interventions - Groups: clarithromycin, 250 mg capsules every 12 hours (n = 128); penicillin VK, 250
mg caps every 6 hours (n = 115)
- Duration of treatment: clarithromycin 8 to 10 days; penicillin VK 10 to 14 days
- Duration of follow-up: 15 to 56 days
Outcomes - Clinical outcomes at 2 to 10 days post-treatment: cure (pre-treatment signs and symp-
toms resolved); improvement (symptoms improved but not totally resolved); failure
(symptoms not improved or worsened); indeterminate (clinical response could not be
assigned because of non-compliance or other reasons)
- Relapse 15 to 56 days post-treatment
- Adverse effects
- Bacteriological outcomes
- Blood haematology and chemistry
- Urinalysis
Notes - Funding: not reported
- Informed consent obtained
- Ethics approval: “the study was approved by local ethics committees”
- No ITT for efficacy, but ITT for adverse effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised” but no descrip-
tion of randomisation sequence
Allocation concealment (selection bias) Unclear risk Not described.
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Levenstein 1991 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Description of medication and placebo to
ensure blinding.
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts accounted for the bacteriologi-
cal outcome analysis, but not for the clini-
cal outcome analysis (only 125 of 243 ran-
domised participants included in clinical
outcome analysis)
48.6% post-randomisation dropout
No ITT for clinical outcomes.
Selective reporting (reporting bias) Unclear risk Safety analysis on all 243 randomised par-
ticipants; clinical and bacteriological out-
come on only 125 participants
Other bias Unclear risk Funding: not reported
McCarty 1992a
Methods - RCT
- Double-blinded
- Double-dummy
Participants - Number of enrolled participants: 218
- Number of participants randomised: 218 (31 negative culture)
- Number of participants evaluated: 171 (78.4%)
- Number of dropouts: 47 (22%)
- Setting: 12 study centres in North America
- Age: > 12 years
- Diagnosis: rapid antigen test, throat culture
- Inclusion criteria: clinical diagnosis of streptococcal pharyngitis or tonsillitis - inflam-
mation of pharynx and tonsils with pain in the throat, with or without fever or exudate,
rapid antigen test or throat culture positive for GABHS
- Exclusion criteria: pregnancy, lactation, history of renal impairment (serum creatinine
levels ≥ 177 µmol/L, 2.0 mg/dL), physical or mental condition that might preclude
evaluation of response, possible future need for other systemic antibiotic during study, use
of antibiotic therapy within 3 days of pre therapy evaluation, use of other investigational
agents within previous 28 days, hypersensitivity to beta-lactam antibiotic
Interventions - Groups: loracarbef oral suspension 15 mg/kg/day 2 doses, daily max. 375 mg, or 200
mg caps 2 per day (n = 107); penicillin VK oral suspension 20 mg/kg/day 4 doses daily
max. 500 mg, or 250 mg caps 4 per day (n = 111)
- Duration of treatment: 10 days
- Duration of follow-up: 28 to 35 days
41Different antibiotic treatments for group A streptococcal pharyngitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCarty 1992a (Continued)
Outcomes - Clinical outcomes at 3 to 5 days post-treatment: cure (total alleviation of difficulty
in swallowing, pharyngeal pain); improvement (substantial improvement in signs and
symptoms); failure (signs and symptoms not substantially alleviated); relapse (initial
improvement or alleviation of symptoms, but subsequent worsening or recurrence);
unable to evaluate
- Relapse at 28 to 35 days post-treatment
- Adverse effects
- Bacteriological outcomes
Notes - Funding: Eli Lilly and Company
- Informed consent obtained
- Ethics approval: not mentioned
- No ITT reported for efficacy, but ITT reported for adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised”; no description
of randomisation sequence
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “In order tomaintain blinding, placebowas
administered twice daily to participants in
the loracarbef group so that all participants
received 4 doses daily.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts: 18 in loracarbef group and 29
in penicillin group. Reasons for dropout:
negative culture (L12 and P19) insufficient
therapy, incomplete data, use of other an-
tibiotic, noncompliance, lack of post-ther-
apy culture)
21.6% post-randomisation dropout
No ITT for clinical outcome.
Selective reporting (reporting bias) Unclear risk ITT for adverse events analysis.
Other bias High risk Funding: Eli Lilly and Company
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Muller 1992
Methods - RCT
- Double-blind
Participants - Number of enrolled participants: 344
- Number of participants randomised: 344
- Number of participants evaluated: 239 (69.5%)
- Number of dropouts: 105 (31%)
- Setting: study centres in Europe and Israel
- Age: 3 to 80 years (mean 28.2) 10.8% < 12 years, 2.0% > 65 yrs
- Diagnosis: rapid antigen test and confirmed by throat culture
- Inclusion criteria: clinical diagnosis of streptococcal pharyngitis or tonsillitis and a posi-
tive rapid streptococcal antigen test. Selections were made on the basis of a demonstrated
history of therapeutic compliance on the part of the patient and/or the patient’s parent/
guardian
- Exclusion criteria: pregnant or nursing or history of renal impairment; any condition,
including significant underlying disease or concomitant infection, which in the opinion
of the investigator could have precluded evaluation of response; anticipated need for
systemic antibiotics; use of antibiotic < 3 days; or hypersensitivity to penicillins and/or
cephalosporins
Interventions - Groups: 1) loracarbef (n = 169) suspension of 15 mg/kg/day in 2 divided doses up to
a max daily dose 375 mg or as a 200 mg capsule twice daily, with placebo twice daily to
maintain double-blind conditions. 2) penicillin V (n = 175 suspension of 20 mg/kg/day
in 4 divided doses up to a max daily dose of 500 mg or as 250 mg capsules) 4 times daily
- Duration of treatment: 10 days
- Duration of follow-up: 38 to 45 days
-Concomitantmedication for treatment of underlying diseases or conditionswas allowed
with the exception of systemic antibiotics. During therapy paracetamol was used by 5.
5% of the patients
Outcomes - Clinical outcomes at days 4 to 6: the patients’ symptomatic responses and adherence to
the treatment regimen; at days 13 to 15): physical examination to determine symptomatic
response to therapy; at days 38 to 45: physical examination to evaluate possible recurrence
of pharyngitis or tonsillitis. Throat cultures were required at every observation period
- Global symptomatic response based on symptom score (difficulty in swallowing, pha-
ryngeal pain, pharyngeal redness, tonsillar inflammation, tonsillar swelling and temper-
ature): cure, improvement (substantial), failure, relapse, or unable to evaluate
- Relapse: no definition given
- A patient was discontinued from the study if the pathogen isolated from initial culture
was resistant to study antibiotic; if there was obvious symptomatic failure of the study
antibiotic at any time during treatment; if there was a significant adverse event or a
clinically significant alteration in a laboratory parameter; if a patient or parent/guardian
wished to withdraw from the study; if the blinding was broken for safety reasons; or if
the patient had an elevated pre-therapy serum creatinine
- Adverse events: at least one adverse event was reported by loracarbef = 22 (13.0%)
and penicillin V = 19 (10.9%) patients. Headache and nausea/vomiting were the only
2 events reported during therapy by more than 2% of the total population. Headache
was reported by loracarbef = 5/169 (3.0%) and by penicillin V = 4/175 (2.3%) (P = 0.
696). Nausea or vomiting was reported by loracarbef = 2/169 (1.2%) and by penicillin
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Muller 1992 (Continued)
V = 5/175 (2.9%) (P = 0.272). Few patients (approximately 5% of the total population)
reported adverse events during the 28 to 35 day post-therapy follow-up period
Notes - Funding: grants from Lilly Research Centre Ltd.
- Informed consent obtained
- Ethics: “conducted according to ethical committee guidelines, including the Declara-
tion of Helsinki (1983 Venice Amendment)”
- No ITT analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “with placebo twice daily to maintain double-blind condi-
tions.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 54of the 169 (31.9%) loracarbef-treated and 51/115 (29.1%)
penicillin-treated patients did not qualify for efficacy evalua-
tion. The most common reasons for disqualification in each
therapy group were bacteriological (loracarbef = 37, penicillin
V = 3); 12 patients in each group received either insufficient
therapy, had no follow-up data (lost to follow-up) or had in-
complete data; loracarbef = 3 patients and penicillin V = 1
were disqualified from the efficacy analysis due to protocol
violations; loracarbef = 1 patient was disqualified for efficacy
evaluation because of the use of another antibiotic during the
study period, and loracarbef = 1 patient could not be evalu-
ated because the post-therapy evaluation was performed 22
days after discontinuing therapy
Selective reporting (reporting bias) Unclear risk All indicated outcomes are reported.
Other bias High risk Funding: grants from Lilly Research Centre Ltd.
NCT00643149
Methods - RCT
- non-inferiority trial
- 15 May 2003 to 22 May 2004
44Different antibiotic treatments for group A streptococcal pharyngitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00643149 (Continued)
Participants - Number of participants enrolled: target 626 (313 per arm)
- Number of participants randomised: 693
- Number of evaluated (treated) participants: 673 (337 azithromycin and 336 amoxi-
cillin)
- Number of participants discontinued: 125 (56 azithromycin and 69 amoxicillin)
- Age: Children 2 to 12 years
- Setting: Multicentre: 33 centres in North America (6 sites in Canada, 19 in US), Latin
America (3 sites inCosta Rica, 1 inGuatamala), and India (4 sites); Paediatric outpatients
- Acute pharyngitis/tonsillitis based on “erythematous pharyngeal mucosa or thick exu-
date covering the pharynx and tonsillar area, and at least one of the following signs or
symptoms: sore/scratchy throat; pain on swallowing; chills and/or fever; cervical adenopa-
thy; scarlet fever rash on the face and skin folds, or red tongue with prominent papillae
(”strawberry tongue“).”
- Positive rapid antigen detection test or positive culture for GABHS
- GABHS pharyngitis/tonsillitis (tested for susceptibility to azithromycin and amoxi-
cillin)
Interventions - Azithromycin SR 60 mg/kg single dose (n = 337); bacteriological per protocol popu-
lation (n = 245)
- Amoxicillin 45 mg/kg twice daily for 10 days (n = 336); bacteriological per protocol
population (n = 237)
Outcomes - Bacteriological cure (primary outcome)
- Clinical success
- Compliance
- Adverse events
- Time points of assessment: “Test of Cure” at 24 to 28 days after starting study drug;
and long term follow-up on days 38 to 45
Notes - Report provided by Pfizer
- Study supported and conducted by Pfizer
- Protocol No: A0661071
- Outcomes only reported for “Bacteriological Per Protocol Population”, i.e. positive
GABHS culture at recruitment or within 48hrs of starting treatment, at least 8 days of
study medication and assessment at baseline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo matched to the active treatment.
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NCT00643149 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk - In total 693 randomised; 20 were not
treated due to insufficient drug supply at
study site (no more information given)
- Of 673 patients treated 125 patients dis-
continued (56 in azithromycin group and
69 in amoxicillin group); reasons for dis-
continuation provided (more dropout due
to adverse events in azithromycin arm (4.
7% versus 0.9%) and more lack of efficacy
in amoxicillin arm (8.3% versus 3.3%))
Selective reporting (reporting bias) Unclear risk All outcomes reported.
Other bias High risk Study supported and conducted by Pfizer
Nemeth 1999
Methods - RCT, randomised 1:1:1
- Double-blinded
- Double-dummy
Participants - Number of participants enrolled: 919
- Number of positive throat cultures susceptible to study drugs: 725
- Number of participants evaluated: 644
- Number of dropouts: 275 (30%)
- Setting: 25 study centres in US and Canada
- Age: =/> 13 years
- Diagnosis: rapid antigen test, throat culture
- Inclusion criteria: throat culture positive for GABHS, at least 1 clinical sign or symptom
of pharyngitis
- Exclusion criteria: pregnancy, history of rheumatic fever or rheumatic heart disease,
peritonsillar abscess or invasive disease, hypersensitivity to beta-lactam drugs, hepatic
disease, hepatic enzyme levels or serum creatinine > 2 times upper limit of normal,
another systemic antibiotic within 3 days before first dose of study medication or for
which < 5 half-lives had elapsed, enrolled in this study previously, received another
investigational drug within 4 weeks before study admission
Interventions - Groups: cefdinir 600 mg four times a day (n = 305); cefdinir 300 mg twice a day (n =
304); penicillin V 250 mg four times a day (n = 310)
- Duration of treatment 10 days
- Duration of follow-up 17 to 24 days post-therapy
Outcomes - Clinical outcomes at day 4 to 9 after treatment: cure (all signs and symptoms absent
or in satisfactory remission and no further antibiotic therapy required); failure (absence
of significant remission of signs and symptoms or need for further antibiotic therapy);
relapse (worsening of, or absence of significant remission of, signs and symptoms 17 to
24 days post-therapy or need for further antibiotic therapy)
- Relapse at day 17 to 24 after treatment
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Nemeth 1999 (Continued)
- Adverse effects
- Bacteriological outcomes
Notes - Funding: Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan (first author is
employee)
- Informed consent obtained
- Ethics approval: institutional review board approval obtained at each site
- No ITT for efficacy reported, but ITT for adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised”, but no descrip-
tion of the randomisation sequence
Allocation concealment (selection bias) Unclear risk “Patients were randomly assigned in a 1:1:
1 ratio..”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “All participants took the same number of
capsules daily. All regimens were adminis-
tered for 10 days.” No description of the
appearance of the capsules
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts 275: no GABHS at admission
culture (194); failure to return or noncom-
pliance (not specified in which group)
30% dropout
No ITT analysis for clinical outcomes.
Selective reporting (reporting bias) Unclear risk Only clinical cure reported, no symptoms
specified.
Adverse events analysed by ITT: 21 partic-
ipants discontinued due to adverse events
(cefdinir = 17 and penicillin V = 4); differ-
ence between both groups not significant
Other bias High risk Funding: Parke-Davis Pharmaceutical Re-
search, Ann Arbor, Michigan (first author
is employee)
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Norrby 2002
Methods - RCT, randomised 1:1
- Double-blinded
- Double-dummy
Participants - Number of participants enrolled: 398
- Number of participants randomised: 396 (1 negative culture)
- Number of participants evaluated: 395
- Number of dropouts: 34 (9%)
- Setting: 62 centres in 10 countries (Europe, New Zealand, S. Africa)
- Age: 15 to 74 years
- Diagnosis: rapid antigen test, throat culture
- Inclusion criteria: clinical signs and symptoms of acute pharyngitis/tonsillitis, including
sore throat and 1 or more others; presumed diagnosis of acute GABHS pharyngitis/
tonsillitis, based on positive rapid antigen detection test or throat culture within 24 hours
prior to starting study medication
- Exclusion criteria: infection of deep tissues of upper respiratory tract or subpharyngeal
respiratory tract; head or neck cancer; history of rheumatic heart disease or valve disease,
infectious mononucleosis, rash; immunocompromised, impaired renal or hepatic func-
tion, history heart rhythm diseases, severe hypokalaemia, any concomitant condition
likely to preclude assessment of treatment response, non-streptococcal or viral pharyngi-
tis/tonsillitis, chronic streptococcal carrier, environmental risk of reinfection, treatment
with penicillin V, systemic or local antibiotic within 7 days prior to study entry; preg-
nancy, lactation, hypersensitivity to study antibiotic, infection with a pathogen known
to be resistant to study drugs, concurrent treatment with other antibiotic or probenecid,
or any medication that may interact with study medication
Interventions - Groups: telithromycin 800 mg oral once daily (n = 198); penicillin V 500 mg oral 3
times daily (n = 197)
- Duration of treatment: telithromycin 5 days; penicillin V 10 days
- Duration of follow-up: 38 to 45 days
Outcomes - Clinical outcomes at day 16 to 20: cure (improvement, disappearance or return to pre-
infection state of all infection-related signs and symptoms, without additional antibiotic)
; failure (infection-related signs and symptoms unchanged or worsened, or clinical im-
provement but required additional antibiotic, developed new clinical findings consistent
with active infection); indeterminate (missing post-treatment information, discontinued
early for reasons unrelated to study drug)
- Relapse at day 38 to 45
- Adverse effects
- Bacteriological outcomes
- Blood haematology
- Urinalysis
- Mean symptom score reported in second publication; no SD reported
Notes - Funding: Aventis Pharma
- Informed consent obtained
- Ethics approval: “approved by and independent ethics committee in each country”
- Modified ITT (1 patient with negative GABHS excluded)
- 2 publications of same study with different outcomes
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Norrby 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Reported as “randomised (1:1)”; Randomi-
sation not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Blinding was maintained by masking the
tablets in capsules and matching placebo
capsules where appropriate.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT for clinical outcomes excluded one
randomised patient with negative culture;
34 participants discontinued, mainly due
to withdrawal of consent or adverse events;
not clear how these reasonswere distributed
in the 2 groups
Selective reporting (reporting bias) Unclear risk Cure was predefined clinical outcome; ad-
verse events reported
Other bias High risk Funding: Aventis Pharma
O’Doherty 1996
Methods - RCT
- Double-blinded
- Double-dummy
Participants - Number of participants enrolled: 489 (92 negative culture) (Azithromycin 20 mg =
160; Azithromycin 10 mg = 166; Penicillin V = 163)
- Number of participants evaluated: 358
- Number of dropouts: 131 excluded (Azithromycin 20 mg = 57; Azithromycin 10 mg
= 43; Penicillin V = 31) (27%)
- Setting: 19 outpatient clinical centres (Europe)
- Age: 2 to 13 years
- Diagnosis: clinical examination, rapid antigen test
- Inclusion criteria: clinical signs and symptoms suggestive of GABHS pharyngitis/
tonsillitis, rapid antigen test positive for GABHS
- Exclusion criteria: within 72 hours prior to the study other antibiotic which could
interfere with evaluation of therapy, hypersensitivity to macrolide or beta-lactam antibi-
otic, terminal illness or other serious disease, any gastrointestinal condition that might
affect drug absorption, other investigational drug in the previous month or long-acting
penicillin injections within the previous 6 weeks
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O’Doherty 1996 (Continued)
Interventions - Groups: azithromycin suspension single oral dose 10 mg/kg (n = 166); azithromycin
suspension one single dose 20 mg/kg (n = 160); penicillin V solution 50 mg/ml orally 4
times daily (total daily dose 500 to 1000 mg) (n = 163)
- Duration of treatment: azithromycin 3 days; penicillin V 10 days
- Duration of follow-up: 28 to 30 days
Outcomes - Clinical outcomes at day 12 to 14: cure; improvement; failure; relapse
- Relapse at day 28 to 30
- Adverse effects
- Bacteriological outcomes
- Blood haematology and chemistry
- Urinalysis
Notes - Funding: not reported
- Informed consent obtained
- Ethics approval: institutional review board approval obtained
- Definition of outcomes not reported
- No ITT for efficacy, but ITT for adverse effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised”, but no descrip-
tion of randomisation sequence
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Matched placebo suspensions or solutions
were administered to maintain blinding of
the study.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout 131 participants: absence of
pathogen (azithromycin 20 mg = 36;
azithromycin 10 mg = 30; penicillin = 26),
deviation from protocol (azithromycin 20
mg = 10; azithromycin 10 mg = 8; peni-
cillin = 3), adverse event (azithromycin 20
mg = 11; azithromycin 10 mg = 5; peni-
cillin = 2)
27% post-randomisation dropout
No ITT analysis.
Selective reporting (reporting bias) Unclear risk Only clinical (and bacteriological) cure re-
ported, no specific symptoms in outcome
analysis
Adverse events reported with ITT analysis.
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O’Doherty 1996 (Continued)
Other bias Unclear risk Funding: not reported
Randolph 1985
Methods - RCT
- Double-blinded
Participants - Number of eligible participants: 260
- Number of randomised participants: 194
- Number of participants evaluated: 194
- Number of dropouts: 0
- Setting: a private paediatric office
- Age: 2 to 20 years
- Diagnosis: throat culture
- Inclusion criteria: clinically suggestive GABHS pharyngitis
- Exclusion criteria: history of hypersensitivity to penicillin or cephalosporins, antibiotic
within previous 72 hours
Interventions - Groups: cefadroxil 250 mg in 3 doses over next 18 to 24 hours (n = 70); penicillin V
250 mg in 3 doses over next 18 to 24 hours (n = 68); placebo (n = 56)
- Duration of treatment: 10 days
- Duration of follow-up: 4 weeks (only results from examination 18 to 24 hours after
initiation of treatment reported)
Outcomes - Clinical outcomes 24 hours after treatment start assessed by physician: improvement
- Sore throat (numbers only reported in graph)
- Fever (numbers only reported in graph)
- Bacteriological outcomes
Notes - Funding: Mead Johnson and Company
- Ethics approval: not mentioned
- ITT analysis reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “All participants were then assigned by a table of random
numbers...”
Allocation concealment (selection bias) Low risk “Randomization of treatment regimens was performed by
a study nurse so that the evaluating physician, parents and
participants were unaware of which agent was dispensed.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above.
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Randolph 1985 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts (all randomised participants evaluated).
Selective reporting (reporting bias) Unclear risk Specific signs and symptoms reported.
No reporting of adverse events.
Other bias High risk Funding: Mead Johnson and Company
Reed 1991
Methods - RCT
- Double-blinded
Participants - Number of participants enrolled and randomised: 116
- Number of evaluated participants: 93
- Number of dropouts: 23 (20%)
- Setting: 4 primary care offices in US
- Age: > 1 month
- Diagnosis: rapid test, throat culture
- Inclusion criteria: sore throat or poor eating, rapid test positive for GABHS
- Exclusion criteria: allergy to penicillin or cephalosporins, pregnancy, history of renal or
hepatic impairment, significant underlying disease or concomitant infection that could
preclude evaluation of response to treatment, antibiotic in the previous 3 days
Interventions - Groups: cefaclor 20 mg/kg/day in 3 doses (n = 60); penicillin VK 20 mg/kg/day in 3
doses (n = 56)
- Duration of treatment: 10 days
- Duration of follow-up: 28 to 30 days post-therapy
Outcomes - Clinical outcomes (not defined; according to clinician’s impression at 2 days after
treatment completion): cure, improvement, relapse, failure
- Relapse at day 28 to 30
- Adverse effects
- Bacteriological outcomes
- Beta-lactamase enzyme production
Notes - Funding: Eli Lily & Company, Indianapolis, Indiana US
- Informed consent obtained
- Ethics approval not mentioned
- No ITT reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
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Reed 1991 (Continued)
Allocation concealment (selection bias) Low risk “The patient was given a prescription that used a code num-
ber to identify the medication to be used.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The identity of the antibiotic was unknown to the physician
and to the patient, and was randomised by a coding sheet
that was available only to the pharmacists dispensing the
study medication.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts 23: no GABHS on culture (cefaclor 6 and peni-
cillin 2), insufficient therapy (cefaclor 0 and penicillin 1),
no follow-up culture (cefaclor 3 and penicillin 0), other an-
tibiotic (cefaclor 1 and penicillin 2), could not be evaluated
according to investigator (cefaclor 3 and penicillin 5)
20% post-randomisation dropout
No ITT analysis.
Selective reporting (reporting bias) Unclear risk Only clinical (and bacteriological) outcome reported, no
specific symptom outcomes reported
Adverse events reported; no ITT analysis.
Other bias High risk Funding: Eli Lily & Company, Indianapolis, Indiana US
Stein 1991
Methods - RCT
- Double-blinded
- Double-dummy
Participants -Number of participants enrolled and randomised: 128 (clarithromycin 65 and penicillin
63)
- Number of participants with S. pyogenes: 109
- Number of participants evaluated: 95 (clarithromycin 47 and penicillin 48)
- Number of dropouts: 33 (26%)
- Setting: multicentre (not specified)
- Age: 12 to 58 years
- Diagnosis: clinical examination, rapid immunoassay test
- Inclusion criteria: signs and symptoms of streptococcal throat infection, rapid im-
munoassay test positive for GABHS antigen
- Exclusion criteria: age < 12 years, pregnancy, lactation, hypersensitivity to erythromycin
or penicillin, receiving antibiotics, impaired renal or liver function
Interventions - Groups: clarithromycin 250 mg capsule every 12 hours (n = 65); penicillin V 250 mg
capsule every 6 hours (n = 63)
- Duration of treatment: 10 days
- Duration of follow-up: 29 to 35 days
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Stein 1991 (Continued)
Outcomes - Clinical outcomes at day 5 to 7 and at day 14 to 16: cure (complete resolution of signs
and symptoms); improved (considerable resolution of presenting signs and symptoms);
failure (no improvement)
- Relapse at day 29 to 35
- Adverse effects
- Bacteriological outcomes
- Blood haematology and chemistry
- Urinalysis
- Serology (antistreptolysin-O titres, anti-DNase B titres)
Notes - Funding: not reported
- Ethics approval: not mentioned
- No ITT for efficacy, but ITT for adverse effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Random number code” was used, but un-
clear how it was generated
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “In order to maintain blinding of the study
placebo capsules were alternated with clar-
ithromycin capsules every six hours.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts 33 (26%); no description of rea-
sons; no ITT for clinical outcomes
Selective reporting (reporting bias) Unclear risk Clinical (and bacteriological) cure rate re-
ported, no specific symptoms.
Adverse events reported with ITT analysis.
Other bias Unclear risk Funding: not reported
Trickett 1973
Methods - RCT
- Double-blinded
- Double-dummy
Participants - Number of enrolled participants: 96
- Number of participants evaluated: 87
- Number of dropouts: 9 (9%)
- Setting: 3 institutions (regular clinics + emergency rooms )
- Age: > 16 years
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Trickett 1973 (Continued)
- Diagnosis: throat culture
- Inclusion criteria: acute sore throat suggestive of acute streptococcal pharyngitis and/
or tonsillitis, throat culture positive for GABHS
- Exclusion criteria: pregnancy, breast-feeding, antibiotic other than study drugs dur-
ing the trial period, inadequate folate reserves, malabsorption syndrome, haemolytic
anaemia, anti-convulsant therapy (dilantin, primidone), antibiotic 1 week preceding
acute streptococcal infection, renal insufficiency, abnormal liver function, low platelets,
total white cells, neutrophils, haemoglobin, hematocrit; glucose-6-phosphate dehydro-
genase deficiency, systemic lupus erythematosus, history of idiosyncratic or allergic re-
actions to any of the drugs
Interventions - Groups: sulphamethoxazole (SMZ) 400 mg and trimethoprim (TMP) 80 mg 2 tablets
4 times per day (n = 48); penicillin G 250 mg 1 tablet 4 times per day (n = 48)
- Duration of therapy: 10 days
- Duration of follow-up: 28 days
Outcomes - No clinical outcomes reported
- Adverse effects
- Bacteriological outcomes
- Urinalysis
- Creatinine
- Liver function: Serum Glutamic Oxaloacetic Transaminase (SGOT) or Aspartate
transaminase (AST)
Notes - Funding: medication supplied by Hoffmann-LaRoche Inc.
- Ethics approval: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported as “randomised” but no descrip-
tion of randomisation sequence; “both
groups were evenly matched as to age, sex,
physical condition, and concurrent diag-
noses.”
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “all test medications were supplied in indi-
vidually coded bottles of identical appear-
ance and were administered according to
the randomised double blind code.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9 dropouts: lost to follow-up, failed to take
medication or negative on strep A tests (not
specified per group).
No ITT analysis.
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Trickett 1973 (Continued)
Selective reporting (reporting bias) Unclear risk Cure rates reported, not individual symp-
toms.
Adverse events mentioned, but not tested.
Other bias Unclear risk Funding: medication supplied by Hoff-
mann-LaRoche Inc.
Watkins 1997
Methods - RCT
- Double-blinded
- Double-dummy
Participants - Number of participants randomised: 345 (dirithromycin 170 and penicillin 175)
- Number of participants evaluated: 257 (dirithromycin 121 and penicillin 136)
- Number of dropouts: 66 in each group (38%)
- Setting: 15 clinical centres in North America
- Age: > 12 years
- Diagnosis: rapid antigen test, throat culture
- Inclusion criteria: weight > 81 lb, positive throat culture, informed consent, ability to
return for follow-up, negative pregnancy test anduse of a reliablemethodof contraception
during therapy and for 30 days thereafter
- Exclusion criteria: any condition precluding evaluation of response to treatment, sys-
temic antibiotic other than the study antibiotic; hypersensitivity to macrolides, peni-
cillins, cephalosporins, pregnancy, breast-feeding, systemic antibiotic in 7 days before
study; participation in a previous dirithromycin study or any study involving and inves-
tigational drug in the 30 days prior to this study
Interventions - Groups: dirithromycin, 500 mg once daily (n = 170); penicillin VK 250 mg 4 times
daily (n = 175)
- Duration of treatment: 10 days
- Duration of follow-up: 3 to 5 weeks post-treatment
Outcomes - Clinical outcomes 3 to 5 days post-treatment: cure (elimination of signs and symptoms)
; improvement (significant but incomplete resolution of signs and symptoms); relapse
(worsening of signs and symptoms after initial improvement); failure (no improvement
in signs and symptoms during treatment)
- Clinical relapse at 3 to 5 weeks post-treatment not reported
- Adverse effects
- Bacteriological outcomes
Notes - Funding: Eli Lilly and Company (2 authors are employees)
- Ethics approval: not mentioned
- No ITT for efficacy, but ITT for adverse effects
Risk of bias
Bias Authors’ judgement Support for judgement
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Watkins 1997 (Continued)
Random sequence generation (selection
bias)
Low risk Sequence generated by computer pro-
gramme.
Allocation concealment (selection bias) Low risk “The randomisation list was not provided
to the investigators until the study was
complete..”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double dummy design” “This was ac-
complished by giving two bottles to
each patient, one containing 20 tablets
(dirithromycin or placebo) and one con-
taining 40 capsules (penicillin or placebo).
”
Incomplete outcome data (attrition bias)
All outcomes
High risk Description of dropouts in each group: lack
of efficacy (dirithromycin 20; penicillin 26)
, lost to follow-up (dirithromycin 4; peni-
cillin 1), patient’s decision (dirithromycin
3; penicillin 0), entry criteria exclusion
(dirithromycin 25; penicillin 22), proto-
col violation (dirithromycin 8; penicillin 8)
, adverse event (dirithromycin 6; penicillin
9)
38% post-randomisation dropout
No ITT analysis.
Selective reporting (reporting bias) Unclear risk Only clinical cure reported, no specific
symptoms.
Adverse events reported with ITT.
Other bias High risk Funding: Eli Lilly andCompany (2 authors
are employees)
GABHS: group A beta-haemolytic streptococcus
ITT: intention-to-treat analysis
kg: kilogram weight
lb: pound weight
RCT: randomised controlled trial
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adam 1994 Not double-blinded
Adam 1995 Not double-blinded
Adam 1996 Not double-blinded
Adam 2000a Not double-blinded
Adam 2000b Not double-blinded
Adam 2001 Not double-blinded
Aujard 1995 Not double-blinded
Bottaro 2012 Open-label study
Breese 1974 Did not compare 2 different classes of antibiotics
Cohen 2002 Not double-blinded
Cruz 2011 Meta-analysis
Davies 1995 Not only acute GABHS tonsillopharyngitis
De Meyere 1992 Not RCT
Del Mar 2008 Commentary of RCT
Denny 1953 Not double-blinded
Disney 1979 Did not compare 2 different classes of antibiotics
Dykhuizen 1996 Not double-blinded
Esposito 2002 Not double-blinded
Feder 1999 Not double-blinded
Gerber 1986 Not double-blinded
Gerber 1999a Did not report any clinical outcomes
Gooch 1993 Not double-blinded
Granizio 2008 Pooled analysis; not original studies
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(Continued)
Hamill 1993 Not double-blinded
Haverkorn 1971 Not RCT
Did not compare 2 different classes of antibiotics
Holm 1991 Not double-blinded
Howe 1997 Not double-blinded
Kuroki 2013 Open-label study
Lennon 2008 Not double-blinded (investigator blinded only)
Matsen 1974 Did not compare 2 different classes of antibiotics
McCarty 1992b Not double-blinded
McCarty 1994 Not double-blinded
McIsaac 2004 Did not compare 2 different classes of antibiotics
Milatovic 1991 Not double-blinded
Milatovic 1993 Not double-blinded
NCT00393744 Not double-blinded
Pacifico 1996 Not double-blinded
Perkins 1969 Not double-blinded
Pichichero 2000 Not double-blinded
Pichichero 2008 Not double-blinded (investigator blinded only)
Portier 1990 Not double-blinded
Portier 1994 Not double-blinded
Rimoin 2011 Did not compare 2 different classes of antibiotics
Roos 1997 Recurrent sore throat
Sakata 2008 Not double-blinded
Shapera 1973 Not double-blinded
Shvartzman 1993 Not double-blinded
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(Continued)
Siegel 1961 Did not compare 2 different classes of antibiotics
Standaert 1997 Not only acute GABHS tonsillopharyngitis
Stelter 2014 Review of results of tonsillectomy
Stillerman 1970 No information on blinding and no data on clinical outcomes
Stillerman 1986 Not double-blinded
Tack 1997 Not double-blinded
Tack 1998 Not double-blinded
Uysal 2000 Not double-blinded
Van Brusselen 2014 Review of tonsillitis guidelines
Zwart 2000 Did not compare 2 different classes of antibiotics
GABHS: group A beta-haemolytic streptococci
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Eslami 2014
Methods “To compare clinical and bacteriologic responses to intramuscular benzathine penicillin G (BPG) and single dose of
amoxicillin in Group A streptococcal (GAS) pharyngitis.”
Participants “571 children from 6 to 15 years old age, with pharyngitis, who were admitted to 45 elementary and guidance schools
from 7 regions of Education Organization in North-East of Iran, Mashhad. They were screened for enrolment and if
he/she presented pharyngitis with clinical criteria of sore throat, erythema, exudate and tender or enlarged anterior
cervical lymph nodes. Exclusion criteria included reports of antibiotic use, negative throat culture for GAS and history
of allergy to the drugs.”
Interventions “...intramuscular benzathine penicillin G (BPG) and single dose of amoxicillin in Group A streptococcal (GAS)
pharyngitis...”
“Results: In the amoxicillin group, treatment failure was more than the penicillin group (18.9% vs. 6.4%, respectively)
but the difference was not statistically significant (P < 0.05). Both drugs were significantly effective in reducing
pharyngitis manifestations but penicillin was significantly more effective in reducing exudate than amoxicillin.”
Outcomes Clinical and bacteriologic responses.
Notes No information on study design provided in the available abstract. Authors contacted for details
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RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Cephalosporin versus penicillin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of symptoms
post-treatment (ITT analysis)
5 2018 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.55, 1.12]
1.1 Adults 2 1163 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.60, 1.01]
1.2 Children 3 855 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.40, 1.73]
2 Resolution of symptoms
post-treatment (evaluable
participants)
5 1660 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.27, 0.97]
2.1 Adults 2 880 Odds Ratio (M-H, Random, 95% CI) 0.56 [0.24, 1.32]
2.2 Children 3 780 Odds Ratio (M-H, Random, 95% CI) 0.46 [0.14, 1.52]
3 Resolution of symptoms within
24 hours of treatment (ITT
analysis)
1 138 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.34, 2.74]
3.1 Children 1 138 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.34, 2.74]
4 Sore throat (ITT analysis) 1 138 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.23, 4.04]
5 Fever (ITT analysis) 1 138 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.19, 4.98]
6 Incidence of relapse (evaluable
participants)
4 1386 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.30, 0.99]
6.1 Adults 2 770 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.20, 0.88]
6.2 Children 2 616 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.33, 2.45]
7 Complications (ITT analysis) 1 244 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Adverse events (ITT analysis) 3 1279 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.27, 3.25]
9 Resolution of symptoms ITT
(subgroup sponsored versus no
sponsor reported)
5 2018 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.55, 1.12]
9.1 Sponsor not reported 2 769 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.27, 0.81]
9.2 Sponsored studies 3 1249 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.70, 1.16]
Comparison 2. Macrolide versus penicillin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of symptoms
post-treatment (ITT analysis)
6 1728 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.92, 1.35]
1.1 Adults 5 1239 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.86, 1.34]
1.2 Children 1 489 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.85, 1.84]
2 Resolution of symptoms
post-treatment (evaluable
participants only)
6 1159 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.57, 1.09]
2.1 Adults 5 801 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.59, 1.31]
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2.2 Children 1 358 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.36, 1.11]
3 Sore throat post-treatment (ITT
analysis)
2 371 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.64, 1.46]
4 Fever post-treatment (ITT
analysis)
2 371 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.69, 1.59]
5 Incidence of relapse (evaluable
participants)
6 802 Odds Ratio (M-H, Random, 95% CI) 1.21 [0.48, 3.03]
5.1 Adults 5 495 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.34, 2.39]
5.2 Children 1 307 Odds Ratio (M-H, Random, 95% CI) 3.10 [0.67, 14.25]
6 Adverse events (ITT analysis) 6 1727 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.82, 1.73]
6.1 Adults 5 1238 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.75, 1.50]
6.2 Children 1 489 Odds Ratio (M-H, Random, 95% CI) 2.33 [1.06, 5.15]
7 Resolution of symptoms ITT
(subgroup sponsored versus no
sponsor reported)
6 1728 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.92, 1.35]
7.1 Sponsor not reported 3 860 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.84, 1.48]
7.2 Sponsored studies 3 868 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.85, 1.46]
Comparison 3. Azithromycin versus amoxicillin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical cure at 24-28 days
(ITT)
1 673 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.55, 1.05]
1.1 Children 1 673 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.55, 1.05]
2 Clinical cure at 24-28 days
(bacteriological per protocol
population)
1 482 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.11, 0.73]
2.1 Children 1 482 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.11, 0.73]
3 Relapse on day 38-45 (ITT) 1 673 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.55, 1.02]
3.1 Children 1 673 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.55, 1.02]
4 Relapse on day 38-45
(bacteriological per protocol)
1 422 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.43, 1.82]
4.1 Children 1 422 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.43, 1.82]
5 Adverse events (all patients) 1 673 Odds Ratio (M-H, Fixed, 95% CI) 2.67 [1.78, 3.99]
5.1 Children 1 673 Odds Ratio (M-H, Fixed, 95% CI) 2.67 [1.78, 3.99]
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Comparison 4. Carbacephem versus penicillin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of symptoms
post-treatment (ITT analysis)
3 795 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.49, 0.99]
1.1 Adults 2 562 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.46, 1.22]
1.2 Children 1 233 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.33, 0.99]
2 Resolution of symptoms
post-treatment (evaluable
participants)
3 602 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.38, 1.01]
2.1 Adults 2 410 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.31, 1.13]
2.2 Children 1 192 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.32, 1.38]
3 Incidence of relapse (evaluable
participants)
3 523 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.64, 2.50]
4 Adverse events (ITT analysis) 3 795 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.75, 1.55]
Comparison 5. Clindamycin versus ampicillin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events (ITT analysis) 1 314 Odds Ratio (Peto, Fixed, 95% CI) 0.41 [0.15, 1.10]
Comparison 6. Sulfonamide versus penicillin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse events (ITT analysis) 1 87 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [0.43, 4.34]
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Analysis 1.1. Comparison 1 Cephalosporin versus penicillin, Outcome 1 Resolution of symptoms post-
treatment (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 1 Resolution of symptoms post-treatment (ITT analysis)
Study or subgroup Cephalosporin Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adults
Carbon 1995 13/119 22/125 15.5 % 0.57 [ 0.27, 1.20 ]
Nemeth 1999 201/609 117/310 36.0 % 0.81 [ 0.61, 1.08 ]
Subtotal (95% CI) 728 435 51.5 % 0.78 [ 0.60, 1.01 ]
Total events: 214 (Cephalosporin), 139 (Penicillin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
2 Children
Disney 1992a 8/263 21/262 13.1 % 0.36 [ 0.16, 0.83 ]
Henness 1982 38/114 33/100 21.2 % 1.02 [ 0.57, 1.80 ]
Reed 1991 22/60 16/56 14.3 % 1.45 [ 0.66, 3.16 ]
Subtotal (95% CI) 437 418 48.5 % 0.83 [ 0.40, 1.73 ]
Total events: 68 (Cephalosporin), 70 (Penicillin)
Heterogeneity: Tau2 = 0.29; Chi2 = 6.23, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 1165 853 100.0 % 0.79 [ 0.55, 1.12 ]
Total events: 282 (Cephalosporin), 209 (Penicillin)
Heterogeneity: Tau2 = 0.07; Chi2 = 7.19, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 1.2. Comparison 1 Cephalosporin versus penicillin, Outcome 2 Resolution of symptoms post-
treatment (evaluable participants).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 2 Resolution of symptoms post-treatment (evaluable participants)
Study or subgroup Cephalosporin Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adults
Carbon 1995 13/119 14/117 22.0 % 0.90 [ 0.40, 2.01 ]
Nemeth 1999 19/427 24/217 25.5 % 0.37 [ 0.20, 0.70 ]
Subtotal (95% CI) 546 334 47.5 % 0.56 [ 0.24, 1.32 ]
Total events: 32 (Cephalosporin), 38 (Penicillin)
Heterogeneity: Tau2 = 0.25; Chi2 = 2.87, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 1.32 (P = 0.19)
2 Children
Disney 1992a 8/263 21/262 21.5 % 0.36 [ 0.16, 0.83 ]
Henness 1982 3/79 16/83 14.4 % 0.17 [ 0.05, 0.59 ]
Reed 1991 9/47 6/46 16.6 % 1.58 [ 0.51, 4.86 ]
Subtotal (95% CI) 389 391 52.5 % 0.46 [ 0.14, 1.52 ]
Total events: 20 (Cephalosporin), 43 (Penicillin)
Heterogeneity: Tau2 = 0.80; Chi2 = 7.45, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 935 725 100.0 % 0.51 [ 0.27, 0.97 ]
Total events: 52 (Cephalosporin), 81 (Penicillin)
Heterogeneity: Tau2 = 0.32; Chi2 = 10.42, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
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Analysis 1.3. Comparison 1 Cephalosporin versus penicillin, Outcome 3 Resolution of symptoms within 24
hours of treatment (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 3 Resolution of symptoms within 24 hours of treatment (ITT analysis)
Study or subgroup Cephalosporin Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Children
Randolph 1985 8/70 8/68 100.0 % 0.97 [ 0.34, 2.74 ]
Total (95% CI) 70 68 100.0 % 0.97 [ 0.34, 2.74 ]
Total events: 8 (Cephalosporin), 8 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Cephalosporin versus penicillin, Outcome 4 Sore throat (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 4 Sore throat (ITT analysis)
Study or subgroup Cephalosporin Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Randolph 1985 4/70 4/68 100.0 % 0.97 [ 0.23, 4.04 ]
Total (95% CI) 70 68 100.0 % 0.97 [ 0.23, 4.04 ]
Total events: 4 (Cephalosporin), 4 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Cephalosporin versus penicillin, Outcome 5 Fever (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 5 Fever (ITT analysis)
Study or subgroup Cephalosporin Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Randolph 1985 3/70 3/68 100.0 % 0.97 [ 0.19, 4.98 ]
Total (95% CI) 70 68 100.0 % 0.97 [ 0.19, 4.98 ]
Total events: 3 (Cephalosporin), 3 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Cephalosporin versus penicillin, Outcome 6 Incidence of relapse (evaluable
participants).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 6 Incidence of relapse (evaluable participants)
Study or subgroup Cephalosporin Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adults
Carbon 1995 3/115 7/115 18.3 % 0.41 [ 0.10, 1.64 ]
Nemeth 1999 11/374 11/166 47.4 % 0.43 [ 0.18, 1.01 ]
Subtotal (95% CI) 489 281 65.7 % 0.42 [ 0.20, 0.88 ]
Total events: 14 (Cephalosporin), 18 (Penicillin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.020)
2 Children
Disney 1992a 2/263 3/262 10.8 % 0.66 [ 0.11, 3.99 ]
Reed 1991 6/45 6/46 23.6 % 1.03 [ 0.30, 3.46 ]
Subtotal (95% CI) 308 308 34.3 % 0.89 [ 0.33, 2.45 ]
Total events: 8 (Cephalosporin), 9 (Penicillin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Total (95% CI) 797 589 100.0 % 0.55 [ 0.30, 0.99 ]
Total events: 22 (Cephalosporin), 27 (Penicillin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.55, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Chi2 = 1.39, df = 1 (P = 0.24), I2 =28%
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Analysis 1.7. Comparison 1 Cephalosporin versus penicillin, Outcome 7 Complications (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 7 Complications (ITT analysis)
Study or subgroup Cephalosporin Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carbon 1995 0/119 0/125 Not estimable
Total (95% CI) 119 125 Not estimable
Total events: 0 (Cephalosporin), 0 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours cephalosporin Favours penicillin
Analysis 1.8. Comparison 1 Cephalosporin versus penicillin, Outcome 8 Adverse events (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 8 Adverse events (ITT analysis)
Study or subgroup cephalosporin penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carbon 1995 14/119 34/125 33.1 % 0.36 [ 0.18, 0.71 ]
Nemeth 1999 183/609 48/310 35.7 % 2.34 [ 1.65, 3.34 ]
Reed 1991 13/60 13/56 31.1 % 0.91 [ 0.38, 2.19 ]
Total (95% CI) 788 491 100.0 % 0.94 [ 0.27, 3.25 ]
Total events: 210 (cephalosporin), 95 (penicillin)
Heterogeneity: Tau2 = 1.09; Chi2 = 24.36, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Cephalosporin versus penicillin, Outcome 9 Resolution of symptoms ITT
(subgroup sponsored versus no sponsor reported).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 1 Cephalosporin versus penicillin
Outcome: 9 Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)
Study or subgroup Cephalosporin Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Sponsor not reported
Carbon 1995 13/119 22/125 15.5 % 0.57 [ 0.27, 1.20 ]
Disney 1992a 8/263 21/262 13.1 % 0.36 [ 0.16, 0.83 ]
Subtotal (95% CI) 382 387 28.5 % 0.47 [ 0.27, 0.81 ]
Total events: 21 (Cephalosporin), 43 (Penicillin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0070)
2 Sponsored studies
Henness 1982 38/114 33/100 21.2 % 1.02 [ 0.57, 1.80 ]
Nemeth 1999 201/609 117/310 36.0 % 0.81 [ 0.61, 1.08 ]
Reed 1991 22/60 16/56 14.3 % 1.45 [ 0.66, 3.16 ]
Subtotal (95% CI) 783 466 71.5 % 0.90 [ 0.70, 1.16 ]
Total events: 261 (Cephalosporin), 166 (Penicillin)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.08, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 1165 853 100.0 % 0.79 [ 0.55, 1.12 ]
Total events: 282 (Cephalosporin), 209 (Penicillin)
Heterogeneity: Tau2 = 0.07; Chi2 = 7.19, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 4.46, df = 1 (P = 0.03), I2 =78%
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Analysis 2.1. Comparison 2 Macrolide versus penicillin, Outcome 1 Resolution of symptoms post-treatment
(ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 2 Macrolide versus penicillin
Outcome: 1 Resolution of symptoms post-treatment (ITT analysis)
Study or subgroup Macrolide Penicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Bachand 1991 28/65 27/63 8.1 % 1.01 [ 0.50, 2.03 ]
Levenstein 1991 64/128 58/115 15.9 % 0.98 [ 0.59, 1.63 ]
Norrby 2002 100/198 91/197 23.5 % 1.19 [ 0.80, 1.76 ]
Stein 1991 20/65 20/63 7.3 % 0.96 [ 0.45, 2.02 ]
Watkins 1997 75/170 74/175 21.2 % 1.08 [ 0.70, 1.65 ]
Subtotal (95% CI) 626 613 76.1 % 1.07 [ 0.86, 1.34 ]
Total events: 287 (Macrolide), 270 (Penicillin)
Heterogeneity: Chi2 = 0.50, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Children
O’Doherty 1996 133/326 58/163 23.9 % 1.25 [ 0.85, 1.84 ]
Subtotal (95% CI) 326 163 23.9 % 1.25 [ 0.85, 1.84 ]
Total events: 133 (Macrolide), 58 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 952 776 100.0 % 1.11 [ 0.92, 1.35 ]
Total events: 420 (Macrolide), 328 (Penicillin)
Heterogeneity: Chi2 = 0.93, df = 5 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 2.2. Comparison 2 Macrolide versus penicillin, Outcome 2 Resolution of symptoms post-treatment
(evaluable participants only).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 2 Macrolide versus penicillin
Outcome: 2 Resolution of symptoms post-treatment (evaluable participants only)
Study or subgroup Macrolide Penicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Bachand 1991 6/43 11/47 11.1 % 0.53 [ 0.18, 1.59 ]
Levenstein 1991 3/67 1/58 1.3 % 2.67 [ 0.27, 26.41 ]
Norrby 2002 17/115 13/119 13.3 % 1.41 [ 0.65, 3.06 ]
Stein 1991 2/47 5/48 5.8 % 0.38 [ 0.07, 2.08 ]
Watkins 1997 26/121 35/136 31.6 % 0.79 [ 0.44, 1.41 ]
Subtotal (95% CI) 393 408 63.1 % 0.88 [ 0.59, 1.31 ]
Total events: 54 (Macrolide), 65 (Penicillin)
Heterogeneity: Chi2 = 4.24, df = 4 (P = 0.37); I2 =6%
Test for overall effect: Z = 0.65 (P = 0.52)
2 Children
O’Doherty 1996 33/226 28/132 36.9 % 0.64 [ 0.36, 1.11 ]
Subtotal (95% CI) 226 132 36.9 % 0.64 [ 0.36, 1.11 ]
Total events: 33 (Macrolide), 28 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 619 540 100.0 % 0.79 [ 0.57, 1.09 ]
Total events: 87 (Macrolide), 93 (Penicillin)
Heterogeneity: Chi2 = 5.07, df = 5 (P = 0.41); I2 =1%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Chi2 = 0.85, df = 1 (P = 0.36), I2 =0.0%
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Analysis 2.3. Comparison 2 Macrolide versus penicillin, Outcome 3 Sore throat post-treatment (ITT
analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 2 Macrolide versus penicillin
Outcome: 3 Sore throat post-treatment (ITT analysis)
Study or subgroup Macrolide Penicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bachand 1991 25/65 24/63 32.5 % 1.02 [ 0.50, 2.07 ]
Levenstein 1991 66/128 61/115 67.5 % 0.94 [ 0.57, 1.56 ]
Total (95% CI) 193 178 100.0 % 0.97 [ 0.64, 1.46 ]
Total events: 91 (Macrolide), 85 (Penicillin)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Macrolide versus penicillin, Outcome 4 Fever post-treatment (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 2 Macrolide versus penicillin
Outcome: 4 Fever post-treatment (ITT analysis)
Study or subgroup Macrolide Penicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bachand 1991 22/65 16/63 25.2 % 1.50 [ 0.70, 3.23 ]
Levenstein 1991 61/128 58/115 74.8 % 0.89 [ 0.54, 1.48 ]
Total (95% CI) 193 178 100.0 % 1.05 [ 0.69, 1.59 ]
Total events: 83 (Macrolide), 74 (Penicillin)
Heterogeneity: Chi2 = 1.23, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Macrolide versus penicillin, Outcome 5 Incidence of relapse (evaluable
participants).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 2 Macrolide versus penicillin
Outcome: 5 Incidence of relapse (evaluable participants)
Study or subgroup Macrolide Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adults
Bachand 1991 3/13 3/15 18.2 % 1.20 [ 0.20, 7.31 ]
Levenstein 1991 1/60 0/1 6.0 % 0.08 [ 0.00, 2.73 ]
Norrby 2002 0/1 1/53 6.0 % 11.67 [ 0.32, 422.14 ]
Stein 1991 3/47 2/48 17.8 % 1.57 [ 0.25, 9.84 ]
Watkins 1997 4/121 8/136 29.2 % 0.55 [ 0.16, 1.86 ]
Subtotal (95% CI) 242 253 77.2 % 0.90 [ 0.34, 2.39 ]
Total events: 11 (Macrolide), 14 (Penicillin)
Heterogeneity: Tau2 = 0.23; Chi2 = 4.86, df = 4 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.22 (P = 0.83)
2 Children
O’Doherty 1996 11/199 2/108 22.8 % 3.10 [ 0.67, 14.25 ]
Subtotal (95% CI) 199 108 22.8 % 3.10 [ 0.67, 14.25 ]
Total events: 11 (Macrolide), 2 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Total (95% CI) 441 361 100.0 % 1.21 [ 0.48, 3.03 ]
Total events: 22 (Macrolide), 16 (Penicillin)
Heterogeneity: Tau2 = 0.37; Chi2 = 6.99, df = 5 (P = 0.22); I2 =28%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 1.80, df = 1 (P = 0.18), I2 =44%
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Analysis 2.6. Comparison 2 Macrolide versus penicillin, Outcome 6 Adverse events (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 2 Macrolide versus penicillin
Outcome: 6 Adverse events (ITT analysis)
Study or subgroup Macrolide Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adults
Bachand 1991 37/65 33/63 15.6 % 1.20 [ 0.60, 2.41 ]
Levenstein 1991 7/128 10/115 9.9 % 0.61 [ 0.22, 1.65 ]
Norrby 2002 70/198 69/196 24.3 % 1.01 [ 0.67, 1.52 ]
Stein 1991 25/65 13/63 13.5 % 2.40 [ 1.09, 5.29 ]
Watkins 1997 108/170 118/175 23.2 % 0.84 [ 0.54, 1.31 ]
Subtotal (95% CI) 626 612 86.5 % 1.06 [ 0.75, 1.50 ]
Total events: 247 (Macrolide), 243 (Penicillin)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.50, df = 4 (P = 0.16); I2 =38%
Test for overall effect: Z = 0.34 (P = 0.74)
2 Children
O’Doherty 1996 35/326 8/163 13.5 % 2.33 [ 1.06, 5.15 ]
Subtotal (95% CI) 326 163 13.5 % 2.33 [ 1.06, 5.15 ]
Total events: 35 (Macrolide), 8 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.036)
Total (95% CI) 952 775 100.0 % 1.19 [ 0.82, 1.73 ]
Total events: 282 (Macrolide), 251 (Penicillin)
Heterogeneity: Tau2 = 0.10; Chi2 = 10.22, df = 5 (P = 0.07); I2 =51%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 3.18, df = 1 (P = 0.07), I2 =69%
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Analysis 2.7. Comparison 2 Macrolide versus penicillin, Outcome 7 Resolution of symptoms ITT (subgroup
sponsored versus no sponsor reported).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 2 Macrolide versus penicillin
Outcome: 7 Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)
Study or subgroup Macrolide Penicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Sponsor not reported
Levenstein 1991 64/128 58/115 15.9 % 0.98 [ 0.59, 1.63 ]
O’Doherty 1996 133/326 58/163 23.9 % 1.25 [ 0.85, 1.84 ]
Stein 1991 20/65 20/63 7.3 % 0.96 [ 0.45, 2.02 ]
Subtotal (95% CI) 519 341 47.1 % 1.11 [ 0.84, 1.48 ]
Total events: 217 (Macrolide), 136 (Penicillin)
Heterogeneity: Chi2 = 0.72, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Sponsored studies
Bachand 1991 28/65 27/63 8.1 % 1.01 [ 0.50, 2.03 ]
Norrby 2002 100/198 91/197 23.5 % 1.19 [ 0.80, 1.76 ]
Watkins 1997 75/170 74/175 21.2 % 1.08 [ 0.70, 1.65 ]
Subtotal (95% CI) 433 435 52.9 % 1.12 [ 0.85, 1.46 ]
Total events: 203 (Macrolide), 192 (Penicillin)
Heterogeneity: Chi2 = 0.20, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 952 776 100.0 % 1.11 [ 0.92, 1.35 ]
Total events: 420 (Macrolide), 328 (Penicillin)
Heterogeneity: Chi2 = 0.93, df = 5 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 3.1. Comparison 3 Azithromycin versus amoxicillin, Outcome 1 Clinical cure at 24-28 days (ITT).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 3 Azithromycin versus amoxicillin
Outcome: 1 Clinical cure at 24-28 days (ITT)
Study or subgroup Azithromycin Amoxicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children
NCT00643149 98/337 118/336 100.0 % 0.76 [ 0.55, 1.05 ]
Total (95% CI) 337 336 100.0 % 0.76 [ 0.55, 1.05 ]
Total events: 98 (Azithromycin), 118 (Amoxicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Azithromycin Favours Amoxicillin
Analysis 3.2. Comparison 3 Azithromycin versus amoxicillin, Outcome 2 Clinical cure at 24-28 days
(bacteriological per protocol population).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 3 Azithromycin versus amoxicillin
Outcome: 2 Clinical cure at 24-28 days (bacteriological per protocol population)
Study or subgroup Azithromycin Amoxicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children
NCT00643149 6/245 19/237 100.0 % 0.29 [ 0.11, 0.73 ]
Total (95% CI) 245 237 100.0 % 0.29 [ 0.11, 0.73 ]
Total events: 6 (Azithromycin), 19 (Amoxicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0092)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Azithromycin Favours Amoxicillin
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Analysis 3.3. Comparison 3 Azithromycin versus amoxicillin, Outcome 3 Relapse on day 38-45 (ITT).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 3 Azithromycin versus amoxicillin
Outcome: 3 Relapse on day 38-45 (ITT)
Study or subgroup Azithromycin Amoxicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children
NCT00643149 130/337 153/336 100.0 % 0.75 [ 0.55, 1.02 ]
Total (95% CI) 337 336 100.0 % 0.75 [ 0.55, 1.02 ]
Total events: 130 (Azithromycin), 153 (Amoxicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Azithromycin Favours Amoxicillin
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Analysis 3.4. Comparison 3 Azithromycin versus amoxicillin, Outcome 4 Relapse on day 38-45
(bacteriological per protocol).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 3 Azithromycin versus amoxicillin
Outcome: 4 Relapse on day 38-45 (bacteriological per protocol)
Study or subgroup Azithromycin Amoxicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children
NCT00643149 16/223 16/199 100.0 % 0.88 [ 0.43, 1.82 ]
Total (95% CI) 223 199 100.0 % 0.88 [ 0.43, 1.82 ]
Total events: 16 (Azithromycin), 16 (Amoxicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Azithromycin Favours Amoxicillin
Analysis 3.5. Comparison 3 Azithromycin versus amoxicillin, Outcome 5 Adverse events (all patients).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 3 Azithromycin versus amoxicillin
Outcome: 5 Adverse events (all patients)
Study or subgroup Azithromycin Amoxicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children
NCT00643149 93/337 42/336 100.0 % 2.67 [ 1.78, 3.99 ]
Total (95% CI) 337 336 100.0 % 2.67 [ 1.78, 3.99 ]
Total events: 93 (Azithromycin), 42 (Amoxicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 4.78 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Azithromycin Favours Amoxicillin
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Analysis 4.1. Comparison 4 Carbacephem versus penicillin, Outcome 1 Resolution of symptoms post-
treatment (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 4 Carbacephem versus penicillin
Outcome: 1 Resolution of symptoms post-treatment (ITT analysis)
Study or subgroup Carbacephem Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adults
McCarty 1992a 21/107 34/111 25.1 % 0.55 [ 0.30, 1.03 ]
Muller 1992 68/169 74/175 44.4 % 0.92 [ 0.60, 1.41 ]
Subtotal (95% CI) 276 286 69.5 % 0.75 [ 0.46, 1.22 ]
Total events: 89 (Carbacephem), 108 (Penicillin)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.72, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Children
Disney 1992b 32/120 44/113 30.5 % 0.57 [ 0.33, 0.99 ]
Subtotal (95% CI) 120 113 30.5 % 0.57 [ 0.33, 0.99 ]
Total events: 32 (Carbacephem), 44 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
Total (95% CI) 396 399 100.0 % 0.70 [ 0.49, 0.99 ]
Total events: 121 (Carbacephem), 152 (Penicillin)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.60, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours carbacephem Favours penicillin
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Analysis 4.2. Comparison 4 Carbacephem versus penicillin, Outcome 2 Resolution of symptoms post-
treatment (evaluable participants).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 4 Carbacephem versus penicillin
Outcome: 2 Resolution of symptoms post-treatment (evaluable participants)
Study or subgroup Carbacephem Penicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
McCarty 1992a 3/89 5/82 12.0 % 0.54 [ 0.12, 2.32 ]
Muller 1992 14/115 23/124 46.4 % 0.61 [ 0.30, 1.25 ]
Subtotal (95% CI) 204 206 58.4 % 0.59 [ 0.31, 1.13 ]
Total events: 17 (Carbacephem), 28 (Penicillin)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Children
Disney 1992b 16/104 19/88 41.6 % 0.66 [ 0.32, 1.38 ]
Subtotal (95% CI) 104 88 41.6 % 0.66 [ 0.32, 1.38 ]
Total events: 16 (Carbacephem), 19 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 308 294 100.0 % 0.62 [ 0.38, 1.01 ]
Total events: 33 (Carbacephem), 47 (Penicillin)
Heterogeneity: Chi2 = 0.07, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.83), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours carbacephem Favours penicillin
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Analysis 4.3. Comparison 4 Carbacephem versus penicillin, Outcome 3 Incidence of relapse (evaluable
participants).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 4 Carbacephem versus penicillin
Outcome: 3 Incidence of relapse (evaluable participants)
Study or subgroup Carbacephem Penicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Disney 1992b 9/84 5/70 32.6 % 1.56 [ 0.50, 4.89 ]
McCarty 1992a 5/75 3/67 19.8 % 1.52 [ 0.35, 6.63 ]
Muller 1992 7/108 8/119 47.6 % 0.96 [ 0.34, 2.75 ]
Total (95% CI) 267 256 100.0 % 1.27 [ 0.64, 2.50 ]
Total events: 21 (Carbacephem), 16 (Penicillin)
Heterogeneity: Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours carbacephem Favours penicillin
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Analysis 4.4. Comparison 4 Carbacephem versus penicillin, Outcome 4 Adverse events (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 4 Carbacephem versus penicillin
Outcome: 4 Adverse events (ITT analysis)
Study or subgroup Carbacephem Penicillin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Disney 1992b 22/120 26/113 32.8 % 0.75 [ 0.40, 1.42 ]
McCarty 1992a 31/107 26/111 36.2 % 1.33 [ 0.73, 2.44 ]
Muller 1992 22/169 19/175 31.1 % 1.23 [ 0.64, 2.36 ]
Total (95% CI) 396 399 100.0 % 1.08 [ 0.75, 1.55 ]
Total events: 75 (Carbacephem), 71 (Penicillin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.86, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours carbacephem Favours penicillin
Analysis 5.1. Comparison 5 Clindamycin versus ampicillin, Outcome 1 Adverse events (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 5 Clindamycin versus ampicillin
Outcome: 1 Adverse events (ITT analysis)
Study or subgroup Clindamycin Ampicillin Odds Ratio Weight Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Jackson 1973 6/156 14/158 100.0 % 0.41 [ 0.15, 1.10 ]
Total (95% CI) 156 158 100.0 % 0.41 [ 0.15, 1.10 ]
Total events: 6 (Clindamycin), 14 (Ampicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours clindamycn Favours ampicilin
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Analysis 6.1. Comparison 6 Sulfonamide versus penicillin, Outcome 1 Adverse events (ITT analysis).
Review: Different antibiotic treatments for group A streptococcal pharyngitis
Comparison: 6 Sulfonamide versus penicillin
Outcome: 1 Adverse events (ITT analysis)
Study or subgroup Sulfonamide Penicillin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Trickett 1973 8/44 6/43 100.0 % 1.37 [ 0.43, 4.34 ]
Total (95% CI) 44 43 100.0 % 1.37 [ 0.43, 4.34 ]
Total events: 8 (Sulfonamide), 6 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours sulfonamide Favours penicillin
A P P E N D I C E S
Appendix 1. Previous searches
Our 2012 review update used the search strategy described below. We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) 2012, Issue 10, part of The Cochrane Library, www.thecochranelibrary.com (accessed 19 October 2012), which includes
the Acute Respiratory Infections Group’s Specialised Register,MEDLINE (1966 toOctober week 4, 2012), EMBASE (1974 toOctober
2012) and Web of Science (2010 to October 2012).
In 2010 we searched The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL 2010, Issue 3) which includes
the Acute Respiratory Infections Group’s Specialised Register, MEDLINE (1966 to JulyWeek 4, 2010) and EMBASE (1974 to August
2010).
The following search strategy was used to search MEDLINE and CENTRAL. The MEDLINE search terms were combined with
the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising
version (2008 revision); Ovid format (Lefebvre 2009). The search terms were adapted for EMBASE (Appendix 3).
MEDLINE (Ovid)
1 exp Pharyngitis/
2 pharyngit*.tw.
3 Nasopharyngitis/
4 nasopharyngit*.tw.
85Different antibiotic treatments for group A streptococcal pharyngitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5 rhinopharyngit*.tw.
6 tonsillit*.tw.
7 tonsillopharyngit*.tw.
8 sore throat*.tw.
9 (strep* adj3 throat*).tw.
10 Streptococcal Infections/
11 “group a beta hemolytic streptococc*”.tw.
12 “group a beta haemolytic streptococc*”.tw.
13 gabhs.tw.
14 or/10-13
15 throat*.tw.
16 14 and 15
17 1 or 2 or 3 or 4 or 5 or 7 or 8 or 9 or 16
18 exp Anti-Bacterial Agents/
19 (antibacterial* or anti bacterial*).tw.
20 antibiotic*.tw.
21 or/18-20
22 17 and 21
There were no language or publication restrictions.
Appendix 2. MEDLINE and CENTRAL search strategy
MEDLINE (Ovid)
1 exp Pharyngitis/
2 pharyngit*.tw.
3 Nasopharyngitis/
4 nasopharyngit*.tw.
5 rhinopharyngit*.tw.
6 tonsillit*.tw.
7 tonsillopharyngit*.tw.
8 sore throat*.tw.
9 (throat* adj3 (infect* or inflam*)).tw.
10 (strep* adj3 (throat* or pharyng*)).tw.
11 Streptococcal Infections/
12 Streptococcus pyogenes/
13 (“group a” adj5 streptococc*).tw.
14 gabhs.tw.
15 or/11-14
16 (throat* or pharyng*).tw.
17 15 and 16
18 1 or 2 or 3 or 4 or 5 or 7 or 8 or 9 or 10 or 17
19 exp Anti-Bacterial Agents/
20 (antibacterial* or anti bacterial*).tw.
21 antibiotic*.tw.
22 exp beta-lactams/
23 exp aminoglycosides/
24 exp Macrolides/
25 exp Quinolones/
26 exp Sulfonamides/
27 exp Tetracyclines/
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28 (aminoglycoside* or amoxicillin* or amoxycillin* or ampicillin* or azithromycin* or benzylpenicillin* or beta-lactam* or beta-
lactam* or cefaclor* or cefadroxil or cefalexin or cefdinir or cefditoren or cefixime or cefpodoxime or cefprozil or ceftibuten or cef-
triaxone or cefuroxime or cephalosporin* or clarithromycin or clavulanic acid* or clindamycin or co-amoxyclav* or doripenem or
doxycycline or eratapenem or erythromycin or imipenem or lincomycin or macrolide* or meropenem or moxifloxacin or penicillin*
or phenoxymethylpenicillin* or piperacillin* or quinolone* or roxithromycin* or sulfamethoxazole* or sulfonimide* or tetracycline* or
ticarcillin or trimethoprim*).tw,nm.
29 or/19-28
30 18 and 29
The MEDLINE search terms were combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in
MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (Lefebvre 2011)
Appendix 3. Embase.com (Elsevier) search strategy
#31 #22 AND #30
#30 #25 NOT #29
#29 #26 NOT #28
#28 #26 AND #27
#27 ’human’/de
#26 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#25 #23 OR #24
#24 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR trial:ti OR (doubl* NEXT/1
blind*):ab,ti
#23 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#22 #16 AND #21
#21 #17 OR #18 OR #19 OR #20
#20 aminoglycoside*:ab,ti OR amoxicillin*:ab,ti OR amoxycillin*:ab,ti OR ampicillin*:ab,ti OR azithromycin*:ab,ti OR benzylpeni-
cillin*:ab,ti OR ’beta-lactam’:ab,ti OR ’beta-lactams’:ab,ti OR betalactam*:ab,ti OR cefaclor*:ab,ti OR cefadroxil:ab,ti OR cefalexin:
ab,ti OR cefdinir:ab,ti OR cefditoren:ab,ti OR cefixime:ab,ti OR cefpodoxime:ab,ti OR cefprozil:ab,ti OR ceftibuten:ab,ti OR cef-
triaxone:ab,ti OR cefuroxime:ab,ti OR cephalosporin*:ab,ti OR clarithromycin:ab,ti OR ’clavulanic acid’:ab,ti OR clindamycin:ab,ti
OR ’co-amoxyclav’:ab,ti OR doripenem:ab,ti OR doxycycline:ab,ti OR eratapenem:ab,ti OR erythromycin:ab,ti OR imipenem:ab,ti
OR lincomycin:ab,ti OR
macrolide*:ab,tiORmeropenem:ab,tiORmoxifloxacin:ab,tiORpenicillin*:ab,tiORphenoxymethylpenicillin*:ab,tiORpiperacillin*:
ab,ti OR quinolone*:ab,ti OR roxithromycin*:ab,ti OR sulfamethoxazole*:ab,ti OR
sulfonimide*:ab,ti OR tetracycline*:ab,ti OR ticarcillin:ab,ti OR trimethoprim*:ab,ti
#19 ’beta lactam antibiotic’/exp OR ’aminoglycoside antibiotic agent’/exp OR ’macrolide’/exp OR ’quinolone derivative’/exp OR
’sulfonamide’/exp OR ’tetracycline derivative’/exp
#18 antibiotic*:ab,ti OR antibacterial*:ab,ti OR ’anti-bacterial’:ab,ti OR ’anti-bacterials’:ab,ti
#17 ’antibiotic agent’/exp
#16 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #15
#15 #13 AND #14
#14 throat*:ab,ti OR pharyngit*:ab,ti
#13 #9 OR #10 OR #11 OR #12
#12 gabhs:ab,ti
#11 (’group a’ NEXT/5 streptococc*):ab,ti
#10 ’streptococcus pyogenes’/de
#9 ’streptococcus infection’/de OR ’group a streptococcal infection’/de
#8 (strep* NEAR/3 (throat* OR pharyngit*)):ab,ti
#7 ’streptococcal pharyngitis’/de
#6 ’sore throat’:ab,ti OR ’sore throats’:ab,ti OR (throat* NEAR/3 (infect* OR inflam*)):ab,ti
#5 ’sore throat’/de
#4 tonsillit*:ab,ti OR tonsillopharyngit*:ab,ti
#3 ’tonsillitis’/de
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#2 pharyngit*:ab,ti OR nasopharyngit*:ab,ti OR rhinopharyngit*:ab,ti
#1 ’pharyngitis’/de OR ’rhinopharyngitis’/de OR ’viral pharyngitis’/de
Appendix 4. Web of Science (Thomson Reuters) search strategy
# 6 18 #4 AND #3
Refined by: Publication Years=( 2011 OR 2010 OR 2012 )
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 5 297 #4 AND #3
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 4 1,296,034 Topic=(random* or placebo* or crossover* or “cross over” or ((singl* or doubl*) NEAR/1 blind*) or allocat*)
OR Title=(trial)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 3 1,398 #2 AND #1
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 2 350,460 Topic=(antibiotic* or anti-bacterial* or antibacterial* or aminoglycoside* or amoxicillin* or amoxycillin* or
ampicillin* or azithromycin* or benzylpenicillin* or beta-lactam* or betalactam* or cefaclor* or cefadroxil or
cefalexin or cefdinir or cefditoren or cefixime or cefpodoxime or cefprozil or ceftibuten or ceftriaxone or cefurox-
ime or cephalosporin* or clarithromycin or “clavulanic acid*” or clindamycin or co-amoxyclav* or doripenem
or doxycycline or eratapenem or erythromycin or imipenem or lincomycin or macrolide* or meropenem or
moxifloxacin or penicillin* or phenoxymethylpenicillin* or piperacillin* or quinolone* or roxithromycin* or
sulfamethoxazole* or sulfonimide* or tetracycline* or ticarcillin or trimethoprim*)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
# 1 2,840 Topic=(pharyngit* or nasopharyngit* or rhinopharyngit* or tonsillit* or tonsillopharyngit* or “sore throat” or
“sore throats” or (throat NEAR/2 (infect* or inflam*))) AND Topic=(streptococc* or gabhs)
Databases=SCI-EXPANDED, CPCI-S Timespan=All Years
Lemmatization=On
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WH A T ’ S N E W
Date Event Description
25 March 2016 New search has been performed We updated the searches and identified two new studies.
We excluded one of the studies (Stillerman 1970). Fur-
ther details have been requested from the authors of the
other identified study (Eslami 2014), which is currently
inserted in the ’Studies awaiting classification’ section
25 March 2016 New citation required but conclusions have not changed The review conclusions remain unchanged.
H I S T O R Y
Date Event Description
5 December 2014 New search has been performed This review update includes the Pfizer 2011 study that
was identified in the 2013 review publication and had
been awaiting classification until data became available.
We did not identify any new studies for inclusion in the
2014 updated search.We identified three new trials for
exclusion (Kuroki 2013; Stelter 2014; Van Brusselen
2014). The review conclusions remain unchanged.
5 December 2014 New citation required but conclusions have not
changed
Our conclusions remain unchanged. In this update we
added a ’Summary of findings’ tables and integrated
GRADE assessment into the text of the review
19 October 2012 New search has been performed The updated searches identified five new references.
Four studies were excluded (Bottaro 2012; Cruz
2011; Rimoin 2011; NCT00393744), and we re-
quested results from one completed unpublished study
(NCT00643149).
19 October 2012 New citation required but conclusions have not
changed
Our conclusions remain unchanged.
6 October 2010 Amended Contact details updated.
31 August 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
MVD wrote the protocol. All authors contributed to final editing of the protocol.
ST conducted the searches for this review.
MVD and NK selected trials for the original version of the review. MVD and ADS reviewed searches for the subsequent updates.
HH assisted with the selection process.
MVD, ADS, and NK independently performed quality assessment.
MVD and NK performed data extraction with support from ADS. MVD analysed the data.
MVD wrote the draft review and addressed the reviewers’ comments. MVD updated the review.
All review authors contributed to the discussion and the editing.
D E C L A R A T I O N S O F I N T E R E S T
Mieke L van Driel: None known.
An IM De Sutter: None known.
Hilde Habraken: None known.
Sarah Thorning: None known.
Thierry Christiaens: None known
S O U R C E S O F S U P P O R T
Internal sources
• None received, Other.
External sources
• None received, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the 2010 review, outcomes were split into primary and secondary. The composite outcome ’resolution of symptoms’ was included
as a primary outcome.
In the 2014 update, the risk of bias assessment tool was changed from the Jadad score to the Cochrane risk of bias assessment tool. We
also included a GRADE assessment using the GRADEPro software and added a description of the GRADE assessment of the overall
quality of the evidence to the methods section and text of the review.
Following advice from the Statistical Editor, we changed the analysis method for pooling to a random-effects model as the default.
To be consistent with our protocol (van Driel 2003), we also used a fixed-effect model if there was no substantial heterogeneity, and
compared results in a sensitivity analysis. This was mentioned as a sensitivity analysis in the protocol (van Driel 2003) and is now
described in the Methods section as a subgroup analysis.
We performed subgroup analyses for adults and children where appropriate because this is relevant to clinicians; this was added to the
Methods section.
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Sensitivity analysis: Our protocol planned sensitivity analyses for patients in different settings, per carrier status, or diagnostic criteria
(throat culture or rapid test), publication status (published versus unpublished studies, studies published as abstract versus full text
articles, year of publication). These were replaced with sensitivity analysis of the impact of heterogeneity and of applying a random-
effects and fixed-effect model.
Sensitivity analysis according to methodological quality rated on the Jadad score (van Driel 2003) was abandoned with the introduction
of the Cochrane risk of bias assessment.
The 2016 author team was changed to include Sarah Thorning as an author. Natalja Keber no longer contributed to the review and
was removed as an author.
The outcome ’incidence of relapse’ was added to the Summary of findings table for cephalosporins compared to penicillin.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Streptococcus pyogenes; Ampicillin [therapeutic use]; Anti-Bacterial Agents [∗therapeutic use]; Cephalosporins [therapeutic use];
Clindamycin [therapeutic use]; Macrolides [therapeutic use]; Penicillins [therapeutic use]; Pharyngitis [∗drug therapy; microbiology];
Randomized Controlled Trials as Topic; Streptococcal Infections [∗drug therapy; microbiology]; Sulfonamides [therapeutic use]
MeSH check words
Adult; Child; Humans
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